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Abstract: Arterial thrombosis is the critical event in acute vascular syndromes such as unstable angina
pectoris, myocardial infarction, peripheral ischemia, and stroke. The fate of a forming thrombus is de-
termined by the balance between pro-thrombotic mediators such as tissue factor (TF) and plasminogen
activator inhibitor type 1 (PAI- 1), and anti-thrombotic factors like tissue factor pathway inhibitor (TFPI)
or tissue plasminogen activator (tPA). TF, a 263-residue membrane-bound glycoprotein, is a key protein
for the activation of coagulation; it binds activated factor VII (FVIIa), which in turn activates factor X,
ultimately leading to thrombin formation. TF expression is upregulated by several mediators such as
tumor necrosis factor-￿ (TNF-￿) or thrombin and can be detected in a variety of cell types in atheromatous
plaques. In addition to the classical antithrombotic agents, drugs targeting TF and the TF:FVIIa com-
plex have recently been introduced, since inhibiting the initiation phase may prevent thrombus formation
more efficiently. Moreover, considering the nonhemostatic properties of the TF:VIIa complex, inhibition
of TF may also interfere with the promigratory and proproliferative effects of TF. In the present study
we characterized the effect of compounds, which have been proposed to exert cardioprotective properties
on the expression of prothrombotic markers in the vessel wall, in particular TF expression, by the use
of cellular and in vivo models. In the first project, we demonstrated that alpha-linolenic acid (ALA),
a plantderived n-3 fatty acid, potently inhibits TF expression and activity in vascular smooth muscle
and endothelial cells. This effect was mediated at the transcriptional level by inhibition of the mito-
gen activated protein-kinase pathways and the transcription nuclear factor kappa-light-chain-enhancer
of activated B-cells (NFkappaB or NFkB). In line with this observation mice fed an ALA-rich diet for 2
weeks suffered a significantly delayed thrombotic occlusion following photochemical vessel wall injury as
compared to controls. Moreover we could demonstrate that this antithrombotic effect was partially me-
diated by an inhibitory effect of ALA on platelet activation and aggregation. Hence, ALA may represent
an attractive nutritional intervention with direct dual anti-thrombotic effects. Epigallocatechin-3-gallate
(EGCG) is a polyphenol found in green tea and experimental as well epidemiological studies revealed
important cardioprotective properties of ECGC. Recently EGCG has been characterized as a ligand for
the 67 kDa laminin receptor (67LR). In the second project we demonstrated that activation of the 67LR
by laminin or EGCG inhibits cytokine induced TF expression in endothelial cells via the c-Jun N-terminal
kinases 1 and 2, and identified 67LR as a potential target for the development of novel anti-thrombotic
therapies. Aim of the third project was to investigate whether the natural lipid lowering drug berberine
(BBR), similar to statins, exerts pleiotropic effects on endothelial tissue factor (TF) expression. We
showed that BBR, at physiologically relevant concentrations, enhances TF expression and in parallel
decreases TFPI expression both in human endothelial cells and in arteries of ApoE-/- mice. Analysis of
the mechanisms demonstrated that BBR enhanced cytokine induced TF expression through a posttran-
scriptional mechanism involving stabilization of TF mRNA. BBR may therefore favor the development
of arterial thrombosis, in particular in patients with atherosclerotic lesions since inflammatory environ-
ments are often encountered under these conditions, and its use in clinical practice should be considered
with caution until large-scale clinical trials have evaluated its safety. Finally, in the last project we
characterized the role of the phosphatidylinositol-3 kinase (PI3K) signaling pathway in the vasculature.
The PI3K controls major cellular processes such as cell cycle, proliferation and differentiation. In the
vasculature,p110￿ is the predominant PI3k isoform expressed in endothelial and vascular smooth mus-
cle cells. This study was designed to address the role of p110￿ in endothelial cell and vascular smooth
muscle cell proliferation, migration, and activation, which are critically involved in the pathogenesis of
atherothrombosis. We demonstrated that inhibition of p110￿ differentially regulates smooth muscle and
endothelial cells. In addition to its potent antiproliferative and antimigratory effects on smooth muscle
cells, targeting p110￿ also inhibits the expression of prothrombotic markers on endothelial such as TF
and PAI-1. Considering that specific targeting of p110 isoforms is currently evaluated in different areas of
modern medicine, we propose local p110￿ inhibition as a novel antithrombotic strategy in particular in the
context of drug eluting stent design, in order to prevent restenosis without adding the risk of enhanced
thrombogenicity. In summary this study supports the concept that modulation of TF expression in the
vasculature represents an attractive target in preventing arterial thrombus formation associated with the
development of cardiovascular events and proposes new strategies to inhibit TF expression. Hence, this
work may contribute to the development of new potent antithrombotic drugs.
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I. Summary 
Arterial thrombosis is the critical event in acute vascular syndromes such as 
unstable angina pectoris, myocardial infarction, peripheral ischemia, and stroke. The 
fate of a forming thrombus is determined by the balance between pro-thrombotic 
mediators such as tissue factor (TF) and plasminogen activator inhibitor type 1 (PAI-
1), and anti-thrombotic factors like tissue factor pathway inhibitor (TFPI) or tissue 
plasminogen activator (tPA). TF, a 263-residue membrane-bound glycoprotein, is a 
key protein for the activation of coagulation; it binds activated factor VII (FVIIa), which 
in turn activates factor X, ultimately leading to thrombin formation. TF expression is 
upregulated by several mediators such as tumor necrosis factor-α (TNF-α) or 
thrombin and can be detected in a variety of cell types in atheromatous plaques. In 
addition to the classical antithrombotic agents, drugs targeting TF and the TF:FVIIa 
complex have recently been introduced, since inhibiting the initiation phase may 
prevent thrombus formation more efficiently. Moreover, considering the non-
hemostatic properties of the TF:VIIa complex, inhibition of TF may also interfere with 
the promigratory and proproliferative effects of TF. 
In the present study we characterized the effect of compounds, which have 
been proposed to exert cardioprotective properties on the expression of 
prothrombotic markers in the vessel wall, in particular TF expression, by the use of 
cellular and in vivo models. 
In the first project, we demonstrated that alpha-linolenic acid (ALA), a plant-
derived n-3 fatty acid, potently inhibits TF expression and activity in vascular smooth 
muscle and endothelial cells. This effect was mediated at the transcriptional level by 
inhibition of the mitogen activated protein-kinase pathways and the transcription 
nuclear factor kappa-light-chain-enhancer of activated B-cells (NFkappaB or NFkB). 
In line with this observation mice fed an ALA-rich diet for 2 weeks suffered a 
  
significantly delayed thrombotic occlusion following photochemical vessel wall injury 
as compared to controls. Moreover we could demonstrate that this antithrombotic 
effect was partially mediated by an inhibitory effect of ALA on platelet activation and 
aggregation. Hence, ALA may represent an attractive nutritional intervention with 
direct dual anti-thrombotic effects.  
Epigallocatechin-3-gallate (EGCG) is a polyphenol found in green tea and 
experimental as well epidemiological studies revealed important cardioprotective 
properties of ECGC. Recently EGCG has been characterized as a ligand for the 67 
kDa laminin receptor (67LR). In the second project we demonstrated that activation 
of the 67LR by laminin or EGCG inhibits cytokine induced TF expression in 
endothelial cells via the c-Jun N-terminal kinases 1 and 2, and identified 67LR as a 
potential target for the development of novel anti-thrombotic therapies. 
Aim of the third project was to investigate whether the natural lipid lowering drug 
berberine (BBR), similar to statins, exerts pleiotropic effects on endothelial tissue 
factor (TF) expression. We showed that BBR, at physiologically relevant 
concentrations, enhances TF expression and in parallel decreases TFPI expression 
both in human endothelial cells and in arteries of ApoE-/- mice. Analysis of the 
mechanisms demonstrated that BBR enhanced cytokine induced TF expression 
through a posttranscriptional mechanism involving stabilization of TF mRNA. BBR 
may therefore favor the development of arterial thrombosis, in particular in patients 
with atherosclerotic lesions since inflammatory environments are often encountered 
under these conditions, and its use in clinical practice should be considered with 
caution until large-scale clinical trials have evaluated its safety. 
Finally, in the last project we characterized the role of the phosphatidylinositol-3 
kinase (PI3K) signaling pathway in the vasculature. The PI3K controls major cellular 
processes such as cell cycle, proliferation and differentiation. In the vasculature, 
  
p110α is the predominant PI3k isoform expressed in endothelial and vascular smooth 
muscle cells. This study was designed to address the role of p110α in endothelial cell 
and vascular smooth muscle cell proliferation, migration, and activation, which are 
critically involved in the pathogenesis of atherothrombosis. We demonstrated that 
inhibition of p110α differentially regulates smooth muscle and endothelial cells. In 
addition to its potent antiproliferative and antimigratory effects on smooth muscle 
cells, targeting p110α also inhibits the expression of prothrombotic markers on 
endothelial such as TF and PAI-1. Considering that specific targeting of p110 
isoforms is currently evaluated in different areas of modern medicine, we propose 
local p110α inhibition as a novel antithrombotic strategy in particular in the context of 
drug eluting stent design, in order to prevent restenosis without adding the risk of 
enhanced thrombogenicity. 
In summary this study supports the concept that modulation of TF expression in 
the vasculature represents an attractive target in preventing arterial thrombus 
formation associated with the development of cardiovascular events and proposes 
new strategies to inhibit TF expression. Hence, this work may contribute to the 
development of new potent antithrombotic drugs.  
  
II. Zusammenfassung 
Die arterielle Thromboseentstehung ist der kritische Schritt in der Entstehung 
akuter vaskulärer Ereignisse. Die Entwicklung der arteriellen Thrombose ist durch 
das Gleichgewicht zwischen prothrombotischen Faktoren, wie zum Beispiel 
Gewebethromboplastin (tissue factor, TF) oder PAI-1 (plasminogen activator inhibitor 
type 1) und antithrombotischer Gegenspieler wie TFPI (tissue factor pathway 
inhibitor) oder tPA (tissue plasminogen activator) bestimmt. TF ist ein wichtiger 
Aktivator der Gerinnungskaskade; es bindet den aktivierten Faktor VII (FVIIa), 
welcher im Gegenzug Faktor X (FX) aktiviert und somit die Thrombin Bildung 
einleitet. TF wird innerhalb der atherosklerotischen Plaque in verschiedenen 
Zelltypen synthetisiert und dessen Expression durch etliche Entzündungs Mediatoren 
gesteigert. Da eine Hemmung der Initiierung der Gerinnungskaskade möglicherweise 
eine potentere antithrombotische Wirkung auf die Entstehung der arteriellen 
Thrombose ausübt erscheint die gezielte Hemmung der Aktivität von TF und des 
TF:FVIIa Komplexes eine neue attraktive Strategie darzustellen.  
In der vorliegenden Studie wurden Substanzen, welche bisher aufgrund ihrer 
antiatherogenen Eigenschaften als kardioprotektiv gelten, auf ihr antithrombotisches 
Potential, insbesondere in Bezug auf TF Expression, charakterisiert. 
Im Rahmen des ersten Projekts konnten wir zeigen, dass die pflanzliche n-3 
Fettsäure alpha-Linolen Säure (ALA) TF sowohl in Gefässmuskel als auch 
Endothelzellen auf transkriptioneller Ebene hemmt. Diese Hemmung beruht auf die 
verminderte Aktivität MAP kinasen sowie des Transkriptionsfaktor NFkappaB. 
Desweiteren konnten wir nachweisen, dass ALA die Aktivierung von Plättchen und 
deren Aggregation signifikant hemmt. Entsprechend dieser Beobachtungen führt eine  
ALA-reiche Diät zu einer verzögerten Thromboseentstehung in einem 
entsprechenden Mausmodell der arteriellen Thrombose. 
  
Sowohl experimentelle als auch epidemiologische Studien belegen, die 
kardioprotektiven und antiatherosklerotsichen Effekte des Grüntee Polyphenols 
Epigallocatechin-3-gallate (EGCG). Kürzlich konnte der 67 kDa Laminin Rezeptor 
(67LR) als zellulärer Rezeptor für EGCG charakterisiert werden. In dem zweiten 
Projekt dieser Studie konnten wir nachweisen, dass die Aktivierung von 67LR durch 
EGCG oder die extrazelluläre Matrixkomponente Laminin die Zytokin induzierte 
Expression und Aktivität von TF in Endothelzellen über die c-Jun N-terminal Kinasen 
1 und 2 hemmt. Somit erscheint die Aktivierung von 67LR eine neuartige 
antithrombotische Therapieoption. 
Ansatz des dritten Projektes war es nachzuweisen ob der natürliche Lipidsenker 
Berberine (BBR) ähnliche pleiotrope antithrombotische Effekte auf TF besitzt wie die  
Wirkstoffe aus Stratingruppe. Wir konnte zeigen, dass BBR in physiologisch 
relevanten Konzentrationen, sowohl in den Karotiden behandelter Mäuse, als auch in 
Endothelzellen in vitro, TF überexprimiert und im Gegenzug die Expression von TFPI 
hemmt. Somit führt BBR zu einem signifikanten Anstieg der TF Aktivität in vivo und in 
vitro. Dieser Effekt beruht auf eine eine posttranskriptionelle Stabilisierung der  TF 
mRNA. BBR begünstigt somit im Gegensatz zu den klinisch etablierten Statinen ein 
prothrombotisches Umfeld in der Gefässwand. Diese Beobachtung ist von Relevanz 
insbesondere in Patienten mit vorbestehenden entzündlich veränderten 
atherosklerotischen Plaques in denen erhöhten Zytokinspiegel nachgeweisen 
werden können. Eine klinische Anwendung von BBR als Alternative oder in 
Kombination mit Statinen sollte daher, bei derzeit ausstehender Datenlage in Bezug 
auf den Einfluss von BBR auf die Rate kardiovaskulärer Ereignisse, nur mit Vorsicht 
erwogen werden. 
Thema des letzten Projekts war es die Rolle der Phosphatidylinositol-3 kinase 
(PI3K) auf die Aktivierung von Gefässzellen zu studieren. Die PI3K reguliert 
  
essentiele zelluläre Prozesse wie Zellzyklus, Proliferation und Zelldifferenzierung. In  
der Gefässwand stellt p110α die vorwiegende Isoform der PI3K dar, und ist sowohl in 
Endothel als auch Gefässmuskelzellen nachgewiesen worden. Ziel dieser Studie war 
es den Einfluss von p110α auf die Proliferation, Migrationsfähigkeit sowie Aktivierung   
in Endothel und Gefässmuskelzellen zu charakterisieren, welche in der Pathogenese 
der Atherothrombose eine kritische Rolle spielen. Wir konnten nachweisen, dass die 
Hemmung von p110α Muskel- und Endothelzellen unterschiedlich reguliert. 
Zusätzlich zu dem augeprägten antiproliferativen und antimigratorischen Effekt auf 
Gefässmuskelzellen, führt eine Hemmung der p110α Isoform zu einer Hemmung der 
TF und PAI-1 Expression in zytokinaktivierten Endothelzellen ohne deren 
Proliferation oder Migrationskapazität zu beeinträchtigen. Aufgrund dieser 
Ergebnisse stellt die lokale Hemmung der p110α Isoform in der Gefässwand somit 
eine neue therapeutische Optionen in der Entwicklung von medikamenten-
beschichteten Stents dar, mit dem Ziel der Verhinderung einer lokalen Restenose 
und gleichzeitiger Reduzierung der Thrombogenität des Stents.  
Zusammenfassend bestätigen die vorgestellten Ergebnisse, dass die 
Modulierung der TF Expression in der Gefässwand eine attraktive therapeutische 
Strategie zu Verhinderung der Entstehung arterieller Thrombosen darstellt, welche  
klinisch mit der Entwicklung kardiovaskuläre Ereignisse einhergeht.  
  
III. Tissue factor: structure and functions 
1.Tissue factor in coagulation 
In intact vessels blood circulates as a fluid due to a physiological balance between 
natural procoagulant and anticoagulant factors. The clotting cascade defines a 
complex system of zymogens and enzymatic reactions designed to limit blood loss 
and ultimately restore vascular integrity by formation of a clot following vessel injury. 
Initially initiation of coagulation was thought to be triggered by two distinct pathways: 
the intrinsic, or contact activation, pathway and the extrinsic, or tissue factor, (TF) 
pathway. Even though the two pathways are independently activated, the distinction 
between both of them is blurred since they share a final common pathway and the 
discovery of cross talks between the extrinsic and intrinsic system. The intrinsic 
pathway is activated when blood or plasma comes in contact with subendothelial 
connective tissues or negatively charged surfaces and involves circulating factors 
such as factor XII, factor XI, factor IX, prekallikrein, and high molecular weight 
kininogen [1]. However, since congenital deficiency in contact factors, for example 
factor XII, does not result in an increased bleeding tendency or severe pathologies in 
humans, the role of the contact pathway in the maintenance of normal hemostasis 
has been questioned. 
Coagulation through the TF pathway is activated when blood interacts with TF 
expressing cell surfaces after vascular injury or plaque rupture (figure 1). The initial 
step consists in the reversible binding of the zymogen factor VII (FVII) or the 
activated FVII (FVIIa) to membrane-bound TF [2,3]. This results in the formation of 
both TF:FVII and TF:VIIa complexes. However, only the latter exerts the enzymatic 
activity required for further activation of downstream proteases. Once bound to TF, 
the inactive FVII is converted to FVIIa via limited proteolysis by several plasma 
proteases, such as XIIa, Xa, IXa or thrombin generating a positive feedback loop[4]. 
  
The resulting TF:FVIIa complex is a potent activator of the coagulation cascade and 
is composed of a regulatory subunit, TF, which acts as a cofactor and the serine 
protease VIIa exerting catalytic functions [5]. The TF:VIIa complex activates factor IX 
to factor IXa which in association with VIIIa catalyzes the conversion of factor X to 
Xa. In addition, factor X is directly converted to factor Xa by the TF:FVIIa complex. 
Factor Xa in association with factor Va and divalent calcium form the so called 
prothrombinase complex which cleaves prothrombin to form thrombin [6]. Thrombin 
exerts direct effects on coagulation through conversion of fibrinogen to fibrin, which 
assembles to clots, activation of platelets and activation of various proteases of the 
coagulation cascade such as FVII, FXI, and FV in an auto-feedback loop. Beside its 
well-known role in clot formation functions of thrombin extend from coagulation to 
vascular remodeling processes such as proliferation of vascular smooth muscle and 
endothelial cell or stimulation of growth factor secretion, ultimately leading to 
restoration of vascular integrity [7-10]. 
 
 
  
Figure 1: TF exerts extracellular effects as main trigger of coagulation as well as intracellular effects on signal 
transduction. 
Binding of FVIIa to TF leads to the activation of FIX and FX. This results in thrombin generation and clot formation. The 
erndogenous inhibitor TFPI, binds to FXa thereby suppressing TF:FVIIa activity. Beside induction of the coagulation cascade, 
formation of the TF:FVIIa complex activates intracellular signaling pathways involved in the pathogenesis of  cardiovascular 
disease. Holy et al. Adv Pharmacol, 2010;59:259-92. 
 
2. Tissue factor protein structure 
The TF (thromboplastin, CD142) gene located on chromosome 1 at p21-22 spans a 
12.4 kb region and contains six exons encoding a single transmembrane polypeptide 
chain composed of 263 amino acids [11-14]. The TF protein is divided into three 
domains: an extracellular (219-amino acid), a membrane-spanning (23 amino acids) 
and a cytoplasmic (21 amino acids) region [6]. TF is considered a class I integral 
membrane protein since the amino-terminus of the protein is located extracellularly 
while the cytoplasmic tail contains the carboxy-terminus. Mobility studies on sodium 
dodecyl sulfate gels reveal that the molecular weight of the fully glycosylated protein 
is about 45’000 kDa [15]. The extracellular domain provides two high affinity sites for 
the binding of factor VII to TF. This binding is crucial for the induction of the 
conformal changes required to induce the catalytic activity of factor VII[16, 17]. In 
addition, anchoring of the TF protein to the membrane via the hydrophobic 
transmembrane domain has been demonstrated to be essential for procoagulant 
activity of the TF protein. However the nature of the anchoring domain does not 
seem to play a role[18]. Since deletion of the cytoplasmic tail is not paralleled by an 
impaired TF procoagulant activity [18], recent studies focused on possible non-
hemostatic functions of this domain. Indeed, experiments performed mainly in 
fibroblasts and carcinoma cell lines revealed that phosphorylation of the cytoplasmic 
tail activates intracellular signaling pathways and induces cellular responses which 
are described in the following chapter. 
In 2003 Bogdanov et al. characterized an alternatively spliced (as) form of TF mRNA 
lacking the fifth exon which encodes the transmembrane domain [19]. The translated 
  
TF protein therefore lacks membrane anchorage and is detectable in the plasma as a 
soluble TF protein. The asTF protein has been described in several cell types and up 
to now its contribution to the TF procoagulant activity in the plasma as well as 
thrombus formation in vivo remains barely understood [20, 21]. 
 
 
3.  Tissue factor: a signaling receptor 
The tight link between hemostasis and progression of diseases such as 
atherosclerosis or inflammation provides the evidence for complex interactions 
between the coagulation cascade and pathophysiological processes. In particular 
because of its similarity to class II cytokine receptors recent studies suggested a non-
hemostatic role of TF in several biolodical processes through induction of intracellular 
signaling events [22]. The following chapter provides an overview of TF mediated cell 
signaling. 
Evidence for TF:VIIa induced signaling is derived from experiments in which FVIIa 
binding to TF was shown to induce intracellular calcium transients in different types of 
TF expressing cells [23, 24]. This observation was followed by studies demonstrating 
that binding of factor VIIa to TF induces the activation of  the three major mitogen 
activated protein (MAP) kinase family members p42/p44 MAP kinase, p38 MAP 
kinase and c-Jun N-terminal kinase (JNK) [25, 26]. In fibroblasts the TF-FVIIa 
induced activation of Src-like kinases and the PI3-kinase leads to activation of the 
downstream Rho-like guanosine triphosphatases Rac and Cdc42, leading to 
cytoskeletal reorganization [27]. Interestingly, the induction of kinase activation was 
demonstrated to be dependent on the catalytic activity of factor VIIa because 
inactivated factor VII or anti-TF antibodies blunt these effects [23, 25, 26, 28].   
By activating several kinases the TF:VIIa complex regulates the transcription of 
numerous genes involved in physiological and pathophysiological processes such as 
  
cell migration, cell growth, or apoptosis. Indeed, studies demonstrated that binding of 
factor VIIa to TF induces activation of key transcription factors such as Egr-1 or 
nuclear factor kappa B and the activation of the RNA polymerase A [26, 29]. 
Microarray analysis of the gene product profiles further revealed increased mRNA 
levels of growth factors (i.e. connective tissue growth factors CCN1 and CCN2, 
fibroblast growth factor 5) and inflammatory cytokines (i.e. interleukin-1β, interleukin-
8) following factor VIIa and TF interaction [28, 30].  
The molecular mechanism by whitch the TF:VIIa complex transduces intracellular 
signaling involves G-protein-coupled, protease-activated receptors (PARs) [31, 32]. 
Currently 4 different PARs have been characterized: PAR1, PAR2, PAR3, PAR4. 
There is a growing evidence that TF:VIIa signaling is mediated mainly by PAR2 and 
to a lesser extend by PAR1, while PAR3 and PAR4 do not seem to be involved.  For 
instance in fibroblasts derived from PAR1 knockout mice factor VIIa induced 
response only occurred when TF and PAR2 where co-expressed [30]. Moreover, 
data obtained in a carcinoma cell line demonstrate that antibodies targeting PAR2 
but not PAR1 blunt TF:VIIa induced IL-8 expression and smooth muscle cell 
migration [33]. 
Even though not essential for TF:VIIa induced activation of MAP kinases and gene 
expression the cytoplasmic domain of TF is implicated in cytoskeletal organization 
and cell migration [34, 35]. Protein kinase C mediated phosphorylation of the 
cytoplasmic domain at the serine residues Ser253 and Ser258 enables the 
interaction of the cytoplasmic tail with the actin-binding protein 280 thereby regulating 
actin filament rearrangement [36, 37]. Hence, studies performed in mice lacking the 
cytoplasmic tail of TF demonstrated the crucial role of the cytoplasmic domain in 
vascular smooth muscle migration and vascular remodeling after injury [38]. 
  
Since increasing evidence suggests an essential role of TF as a key signal 
transducer beyond is well-known functions in coagulation, developing specific 
inhibitors that suppress either TF:VIIa mediated signaling or its coagulant function 
may offer interesting therapeutic approaches in the treatment of TF associated 
diseases. 
 
IV. Tissue factor: implications in vascular disease 
1. Tissue factor distribution 
a) Tissue Factor in the vessel wall 
Under normal hemostatic conditions TF is only barely expressed in endothelial cells 
(figure 2). Inflammatory cytokines, such as tumor necrosis factor-α (TNF-α) [39, 40], 
interleukin-1β [41], and mediators including CD40 ligand [4], enhance TF expression 
in vitro. This induction of TF expression is mainly mediated by the mitogen-activated 
protein (MAP) kinases p38, extracellular-signal-regulated kinase (ERK) and c-Jun N-
terminal kinase (JNK) which activate transcription factors such as nuclear factor 
kappa B, activator protein-1 or early growth-response gene product-1, all of them 
involved in the transcription of the TF gene [42-44]. Depending on the stimulus, 
induction of TF expression occurs via activation of either all three MAP kinases [39, 
40, 45] or only a single pathway [44]. Protein kinase C as well as the Rho-kinase 
pathway have also been shown to mediate the induction of endothelial TF expression 
[44, 46, 47]. Whereas the MAP kinase, Rho-kinase and protein kinase C pathways 
regulate TF expression in a positive manner, the phosphoinositide 3-kinase pathway 
exerts a negative regulation on TF expression [48, 49]. Indeed, downstream targets 
of the phosphoinositide 3-kinase are able to regulate TF expression at both the 
transcriptional and the translational level. Akt and glycogen synthase kinase-3β 
regulate TF transcription [50], whereas the mammalian target of rapamycin and 
  
p70S6 kinase inhibit TF translation [49, 51]. An additional mechanism affecting the 
regulation of TF protein expression is stabilization of TF messenger RNA. A recent 
study in endothelial cells demonstrated that a decrease in TF promoter activity may 
be counteracted by an increased TF mRNA stability leading to enhanced TF protein 
expression [39]. 
        In contrast to endothelial cells vascular smooth muscle cells constitutively 
express TF and provide an hemostatic barrier after vascular injury [52-55]. Similar to 
endothelial cells, TF expression in vascular smooth muscle cells is enhanced by 
several receptor ligands such as CD40 ligand, histamine, thrombin, bacterial 
endotoxin, oxidized LDL, or C-reactive protein [55-59]. Even though not investigated 
to the same extend as in endothelial cells, the MAP kinase and phosphoinositide 3-
kinase pathways regulate TF expression also in vascular smooth muscle cells. 
 
 
  
                                                              
 
Figure 2: Expression of TF in different cell types during the pathogenesis of atherosclerotic lesions. 
During plaque progression, the inflammatory environment triggers TF expression in endothelial cells, vascular smooth muscle 
cells, and macrophages/foam cells. On plaque rupture, the procoagulant material including TF-containing microparticles located 
in the necrotic core is released into the blood, leading to rapid initiation of coagulation, thrombus formation, and  vessel 
occlusion. Holy et al. Adv Pharmacol, 2010;59:259-92. 
 
  
b. Blood-borne tissue factor 
More recently TF has been also been detected at low levels in the plasma and urine 
and these levels increase in several disease conditions such as atherosclerosis, 
disseminated intravascular coagulation, glomerulonephritis, sepsis, or diabetes.  
Monocytes are thought to contribute as a major source to the plasmatic TF pool. 
Monocytes constitutively express TF and its expression is enhanced after exposure 
to numerous inflammatory mediators [60-65]. Indeed, elevated levels of TF have 
been measured in the plasma during septic states and may account for the 
thrombotic complications encountered in those patients [66, 67]. Endotoxin-induced 
TF expression is mediated via MAP kinases [63, 64] and the consecutive activation 
of the transcription factors EGR-1, c-Fos/c-Jun and nuclear factor kappa B. In 
addition endotoxin also increases TF mRNA stability [68]. 
TF has also been described in circulating granulocytes and eosinophiles as well as 
neutrophils and basophils have been found to express TF [69-73]. TF translocation to 
the cell surface as well as transcription is enhanced upon stimulation of those cells 
with granulocyte/macrophage colony-stimulating factor or platelet-activating factor 
[69]. These findings may explain the pro-thrombotic state associated with 
hypereosinophilia [74]. 
Even though TF-containing platelets have been described by several groups [70, 75-
78] the role of platelet derived TF remains debatable [79]. In platelets TF is 
encountered in different compartments including the membrane the matrix of α-
granules as well as canalicular system [63], and translocated to the cell surface upon 
activation by different agonists [63]. Since TF messenger RNA is not found in human 
megakaryocytes the source of platelet derived TF remains a matter of debate. One 
hypothesis suggests that TF containing microparticles derived from activated 
monocytes, leucocytes [80] or endothelial cells [81, 82] fuse with the platelet 
  
membrane through a receptor mediated process [77, 80] and thereby deliver TF into 
platelets. However other studies demonstrated the presence of a spliced TF mRNA 
in activated human platelets and confirmed an increased TF protein synthesis and 
activity in ADP stimulated platelets [82]. 
TF containing microparticles have been characterized in the plasma. Beside 
endothelial and vascular smooth muscle cells [69, 83-85], monocytes and platelets 
are the main source of TF containing microparticles [86, 87]. Despite studies 
demonstrating the role of microparticle derived TF in generation of thrombin in vitro 
[88], doubts remain about its contribution to thrombus formation in vivo [89, 90].  
As mentioned previously, the full-length form of TF mRNA contains 6 exons and 
splicing of exon 5 results in a frame-shift mutation generating a soluble alternatively 
spliced TF protein lacking the transmembrane domain [19]. Apart from plasma, 
alternatively spliced TF has been found in several tissues and cell types including the 
lung, placenta, vascular smooth muscle cells, and keratinocytes. Whereas it remains 
unclear whether alternatively spliced TF exerts pro-coagulant activity [91] more 
recent reports have revealed a role of alternatively spliced TF in angiogenesis by 
promoting endothelial cell migration and differentiation [92, 93]. 
 
c. Tissue factor in the heart  
In contrast to skeletal myocytes, cardiac myocytes express the full length form of TF 
under basal conditions [94, 95]. Studies performed in mice expressing low levels of 
TF decrypted a potential role of TF in the maintenance of heart hemostasis. Mice 
expressing low-TF had increased cardiac hemorrhages and hemosiderin depositions 
ultimately leading to cardiac fibrosis and a reduction in left ventricular function as 
compared to wild type animals [96]. Phagocytosis of hematin derived from 
hemorrhaging erythrocytes is thought to play a key role in this process. Interestingly 
  
mice lacking factor IX had normal hearts, underlining the specific role the TF:VIIa 
complex in hemostatic protection of the heart. 
 
2. Tissue factor in cardiovascular diseases 
a) Implications in thrombus formation 
Although TF is critically involved in initiation of the coagulation cascade, questions 
regarding the role and contribution of the different TF pools in arterial thrombus 
formation remain open. 
Under normal hemostatic conditions TF is constitutively expressed in the vascular 
smooth muscle layer of the media and in fibroblasts present in the vessel and the 
adventitia surrounding the blood vessels [97, 98]. Hence, disruption of blood vessel 
integrity promotes the interaction between circulating factor VII and the intravascular 
TF pool leading to initiation of the clotting cascade. Moreover the release of 
inflammatory triggers following vascular injury or plaque rupture induces the 
expression of TF in endothelial cells and circulating cells in the blood thereby 
potentiating a full coagulation response [4]. In contrast to the initiation phase of 
coagulation, the mechanisms underlying the propagation of the clot growth are not as 
evident. 
The first hypothesis introduced blood-borne TF as a major contributor to the 
propagation of the clotting reaction. This consideration is based on the fact that the 
maintenance of coagulation requires a constant activity of TF as a cofactor and that 
the formed fibrin clot isolates and prevents the initially formed TF:VIIa complexes 
from reacting with circulating new inactive coagulation factors [99]. This hypothesis is 
supported by the observation that in the blood TF is detected at very low levels 
unable to trigger a coagulant response whereas the TF concentration reaches 
functionally significant levels on the surface of a forming thrombus [19, 100, 101]. In 
  
addition other studies revealed the presence of embedded TF in murine [90, 102] and 
human [103] thrombi. In vitro, the role of blood-borne TF in coagulation is strengthen 
by the study of Okorie et al. who demonstrate that in contrast to no-flow conditions 
the subpicomolar TF concentrations found in blood cause an increase in thrombin 
formation under flow [104]. 
On the other hand, recent experiments performed in mathematical as well as whole 
blood models revealed different stages of TF requirement in the clotting process and 
showed that after the onset of thrombin generation the propagation of coagulation is 
TF independent [105]. By abrogating TF activity with specific antibodies targeting 
either VIIa or TF, Orfeo et al. distinguished 3 phases in the clotting process:  a first 
short (<10 seconds) period of absolute TF:VIIa dependence; a second period (10-
240 seconds) of partial TF:VIIa dependence that decreases with the progress of the 
reaction, and after 2 minutes a period which is TF:VIIa independent. In addition this 
study also showed that the initial activation of  procoagulant proteases by the TF:VIIa 
complex is sufficient to maintain a pool of activated procoagulant catalysts able to 
maintain a sustained coagulation response in a TF independent manner.  
Since venous thrombosis is not associated with vessel damage, circulating TF may 
play an important role in this pathology. In a model of jugular vein thrombosis 
inhibition of TF reduced thrombus growth in the uninjured vein [106]. However, in 
another study hematopoietic cell-derived TF did not affect venous thrombosis in an 
inferior vena cava thrombosis model in the mouse [90]. 
In summary, the exact role of the different TF pools and their contributions to the 
propagation of clot formation remains controversial and further studies are definitely 
required. 
 
b) Implications in inflammation and atherosclerosis 
  
Inflammation is tightly linked to the development of atherosclerosis [107]. Elevated 
levels of inflammatory cytokines known to induce TF expression, such as TNF-α and 
interleukins, are observed in early atherosclerotic lesions after adhesion and 
infiltration of monocytes to the vessel wall. In the early stages of atherogenesis, TF 
mRNA and antigen is expressed in macrophages [52, 108] and as the lesion 
progresses TF is increasingly expressed in other cell types such as foam cells, 
endothelial cells and smooth muscle cells. Within the necrotic core [109] it is 
predominantly associated with TF containing microparticles synthetized by foam 
cells, monocytes, lymphocytes and smooth muscle cells and encountered in the 
extracellular space [110]. During plaque rupture the content of the core comes in 
contact with the circulating blood and TF originated from the plaque content and from 
activated endothelial and smooth muscle cells triggers thrombus formation and 
thereby acute vascular events. Indeed higher levels of TF are described in the 
atherosclerotic plaques of patients suffering acute coronary syndromes as compared 
with patients suffering stable angina [111]. 
In turn, recent studies indicate that TF:VIIa signaling may play a role in the 
pathogenesis of atherosclerosis. The TF:VIIa complex has been shown to be a strong 
chemotactic stimulus for vascular smooth muscle cells [112]. Inhibition of TF:VIIa by 
overexpression of tissue factor pathway inhibitor lead to a consecutive reduction of 
vascular smooth muscle cell migration in vitro and in vivo impaired vascular 
remodeling in an mouse model [113, 114]. Since TF:VIIa mediated cell signaling 
induces a number of gene products involved in cell proliferation and migration, it is 
very likely similar effects occur within TF expressing cells in atherosclerotic lesions. 
As mentioned in the previously TF:VIIa signaling enhances the expression of the 
connective tissue growth factors CCN1 and CCN2 in fibroblasts and vascular smooth 
muscle cells.39 Interestingly, similar to TF, CCN1 and CCN2 mRNA levels are highly 
  
expressed in atherosclerotic lesions of apoE-/- mice and in human atherosclerotic 
plaques [115, 116]. Hence, it is conceivable that by inducing the expression of CCN1 
and CCN2, the TF:VIIa complex promotes plaque progression via enhanced 
extracellular matrix accumulation and vascular smooth muscle cell proliferation. In 
addition a role of CCN1 and CCN2 in monocyte and platelet adhesion to the 
subendothelial matrix after endothelial injury has also been described [117, 118]. 
In response to inflammatory mediators TF transcription can be induced in different 
cell types. Vice versa, recent results show that TF on these cells appears to regulate 
the inflammatory response. During sepsis the TF pathway induces a lethal 
inflammatory exacerbation independently of  thrombin generation and clot formation 
[119, 120]. Inhibition of the TF:VIIa complex was paralleled by a decrease in 
interleukin secretion and a reduction in inflammatory infiltrations in several tissue 
during sepsis [121]. This finding is confirmed by the observation that in a model of 
septicemia mice expressing low TF levels display reduced interleukin levels and an 
increased survival compared with control mice [122]. Studies performed in PAR2 
deficient mice suggest that the pro-inflammatory TF:VIIa signaling response is likely 
mediated via PAR2 [122]. However it is worth noting that deficiency of PAR1 or 
PAR2 alone has no effect and that reduction in inflammation and mortality is only 
observed in the context of a combined inhibition of thrombin generation and PAR2 
deficiency, indicating a tight link between coagulation and inflammation. 
 
c) Implications in acute coronary syndromes  
Higher levels of TF have been detected in coronary atherectomy specimens from 
patients with unstable angina or myocardial infarction [123]. In line with this, plasma 
TF levels are elevated in patients with acute coronary syndromes compared with 
controls [124, 125] and have been shown to correlate with an unfavorable outcome in 
  
those patients [126]. In addition, patients with unstable angina or non-ST-elevation 
myocardial infarction and a high TIMI score (≥4) show increased TF plasma levels 
compared with those with a low TIMI score (<3) [127]. 
Percutaneous transcoronary angioplasty and consecutive stent implantation has 
become the gold standard in the treatment of stenotic lesions in acute coronary 
syndromes. The local inflammatory reaction following balloon dilatation and stent 
implantation [128] induces local TF release from the dissected plaque. Thus, mostly 
due to promigratory effects of TF on vascular smooth muscle cells, elevated levels of 
TF have been reported to positively correlate with the incidence of restenosis after 
percutaneous interventions [129]. Despite the reduction in restenosis following 
deployment of drug eluting stents (DES) when compared to bare metal stents, stent 
thrombosis rates have not been decreased with the use of DES and may even be 
higher [130]. One possible explanation may be that the drugs eluting from the stents 
which are intended to inhibit restenosis by reduction of vascular smooth muscle cell 
migration and proliferation also exert biological effects on other cell types in the 
vasculature, in particular endothelial cells. For instance recent studies revealed that 
drugs coating the first and second generation stents, like rapamycin, everolimus or 
zotarolimus, enhance TF expression in endothelial cells and accelerate arterial 
thrombus formation via inhibition of the mTOR/p70S6K pathway [49, 131]. Similarly, 
paclitaxel another widespread stent coating drug was shown to increase endothelial 
TF expression and activity through activation of the MAP kinase JNK [132]. Hence, 
these findings may raise important issues in the context of drug eluting stent design 
since coating a stent with a drug exerting not only antiproliferative but also 
antithrombotic properties may offer new options in the interventional treatment of 
vascular disease. 
 
  
d) Tissue factor and cardiovascular risk factors 
Diabetes mellitus, independently of coronary disease, is associated with an increase 
in plasmatic TF activity [133], TF antigen levels [134] and TF containing 
microparticles [135]. In line with this observation improvement of glycemic control or 
application of oral antidiabetics such as the peroxisome-proliferator-activated 
receptor-γ agonist rosiglitazone downregulate TF protein expression in these patients 
[136]. Consistent with this observation, high glucose increases TF antigen and 
activity in monocytes derived from healthy subjects [137, 138]. A similar effect of high 
glucose on TF expression in human endothelial cells was also observed [139]. In 
diabetes, hyperglycemia induces the formation of advanced glycation end-products 
[78], which upregulate TF expression in endothelial cells and monocytes via nuclear 
factor kappa B [140-142]. Consistent with these findings, higher levels of AGE and 
TF were observed in the vasculature of diabetic mice. Blockade of the corresponding 
receptor for AGE however significantly reduced the TF increase in the aorta of these 
mice[140].  
Patients with hyperlipidemia display an increased risk of developing thrombosis[143]. 
Elevated low density lipoprotein (LDL) levels are associated with an increased TF 
plasma activity [144]. Oxidized LDL triggers TF protein synthesis in monocytes [145], 
endothelial cells [146] and vascular smooth muscle cells [147]. In contrast, high-
density lipoproteins (HDL) reduce thrombin-induced TF expression in endothelial 
cells through PI3K pathway activation [148]. 3-hydroxy-3-methylglutaryl-CoA 
reductase inhibitors (statins) reduce TF expression in monocytes [149], endothelial 
cells [46] and vascular smooth muscle cells [150]. These findings are confirmed in 
studies performed in ApoE -/- mice in which simvastatin and rosuvastatin treatment 
reduced the TF antigen expression in atherosclerotic lesions significantly 
independent of lipid lowering effects [151, 152]. Fibrates, which are also in use as 
  
lipid lowering drugs in the treatment of hyperlipidemia, also exert pleiotropic effects 
on vascular TF expression beyond their lipid lowering properties [153]. 
In contrast to normotensive subjects, hypertensive patients display increased plasma 
levels of TF antigen [154] which can be lowered by an appropriate antihypertensive 
management [155]. Several mechanisms are thought to mediate this enhanced TF 
expression observed in arterial hypertension. For instance the chronic exposure to 
shear stress induces the activation of transcription factors and consequently the 
expression of TF in endothelial cells [156]. On the other hand angiotensin II was 
shown to increase TF expression in monocytes [157], endothelial cells [156] and 
vascular smooth muscle cells via the angiotensin II type 1 receptor. Consistent with 
this observation ACE inhibitors and angiotensin II type 1 receptor antagonists reduce 
TF plasma activity in hypertensive patients and inhibit endotoxin-induced TF 
expression in monocytes [158].  
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Abstract  
 
Objective. Plant-derived alpha-linolenic acid (ALA) may constitute an attractive 
cardioprotective alternative to fish-derived n-3 fatty acids. However, the effect of 
dietary ALA on arterial thrombus formation remains unknown. 
Methods and Results.  Male C57Bl/6 mice were fed a high ALA or low ALA diet for 
2 weeks. Arterial thrombus formation was delayed in mice fed a high ALA diet as 
compared to those on a low ALA diet (n=7; p<0.005). Dietary ALA impaired platelet 
aggregation to collagen and thrombin (n=5; p<0.005) and decreased p38 MAP 
kinase activation in platelets. Dietary ALA impaired arterial tissue factor (TF) 
expression, TF activity and NFκB activity (n=7; p<0.05); plasma clotting times and 
plasma thrombin generation did not differ (n=5; p=NS). In cultured human vascular 
smooth muscle and endothelial cells ALA inhibited TF expression and activity (n=4; 
p<0.01). Inhibition of TF expression occurred at the transcriptional level via the MAP 
kinase p38 in smooth muscle cells and p38, ERK1/2, and JNK1/2 in endothelial cells. 
Conclusions. ALA impairs arterial thrombus formation, TF expression, and platelet 
activation, and thereby represents an attractive nutritional intervention with direct 
dual anti-thrombotic effects. 
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Arterial thrombosis is the critical step in the development of acute vascular 
syndromes.1,2,3 Circulating platelets are activated by interaction with subendothelial 
collagen at the site of an injury.4 In parallel, membrane bound tissue factor (TF) 
expressed on vascular cells acts as a receptor for activated factor VII (VIIa).5,6 The 
TF/VIIa complex triggers the coagulation cascade and the formation of activated 
factor X (Xa) ultimately resulting in thrombin formation, which in turn cleaves 
protease-activated receptors on the platelet surface boosting platelet activation and 
clot formation4. The critical role of platelets and TF in the pathogenesis of acute 
coronary syndromes has indeed been well documented.7,8,9  
Experimental and epidemiological studies have extensively characterized the 
cardioprotective and anti-thrombotic effects of fish-derived dietary long chain n-3 fatty 
acids eicosapentaenoic acid (C20:5 n-3, EPA) and docosahexaenoic acid (C22:6 n-
3, DHA).10,11,12,13 Consistent with these observations, an increased risk for developing 
cardiovascular disease was identified in populations with low intake of EPA and DHA, 
prompting the American Heart Association (AHA) to modify their nutrition 
guidelines.14  
ALA is an essential n-3 FA found at high concentrations in vegetable oils, in 
particular flaxseed oil, where it accounts for 50% of the total FA content. Following 
oral intake, ALA is partially converted into EPA and DHA. The rate of conversion of 
ALA into long chain n-3 fatty acids ranges from 0.05 to 10%.15 In recent 
epidemiological studies, ALA consumption has been inversely associated with the 
incidence of myocardial infarction, sudden cardiac death, and coronary artery 
calcification.16-20 Despite these promising data, the precise biological mechanisms 
mediating the cardioprotective effects of ALA remain barely understood. In particular, 
it remains controversial whether the rather poor conversion of ALA to EPA and DHA 
can account for the beneficial effects of ALA or whether ALA exerts direct biological 
  
effects.21,22  
Since increasing evidence suggests that ALA can serve as a cardioprotective 
nutritional supplement, this study addresses the question whether dietary ALA 
inhibits thrombus formation in vivo and analyzes the mechanisms involved. 
  
Materials and Methods 
 
For the detailed Materials and Methods please see the supplemental Materials and 
Methods (available online at http://atvb.ahajournals. org). 
 
ALA diet and carotid artery thrombosis model  
C57BL/6 mice were fed a 0.21% w/w cholesterol diet containing either a high 
ALA (7.3%) or low ALA concentration (0.03%, supplemental table 1).23 
Photochemical injury model was performed after 2 weeks of treatment. 
 
Immunohistochemistry 
Thrombus composition was analysed in paraffin fixed sections from occluded 
carotid arteries. Sections were stained for TF, fibrin, and the platelet marker CD41. 
 
Prothrombin time (PT) and activated partial thromboplastin time (aPTT) 
Plasma was isolated from citrated blood (3.2%; 1/10) by centrifugation (2500g; 
4°C; 15 minutes). PT and aPTT were assessed using the START 4 analyzer 
(Diagnostica Stago, France). 24 
   
Thrombin generation 
Plasma thrombin generation was monitored by automated calibrated 
thrombography and the results analysed using the Thrombinoscope software 
(Thrombinoscope BV, Maastricht, The Netherlands).25,26  
 
Platelet aggregation 
  
Platelet aggregation was studied by whole blood impedance aggregometry 
(Chrono-Log, Havertown, PA, USA).  
 
Fatty acid profile in aortic tissue 
FA profiles of the pooled tissues were analyzed by gas chromatography as 
described.27 Measurements were performed in duplicate and the mean value 
displayed.  
 
Cell culture 
 Human aortic vascular smooth muscle cells (VSMC; Clonetics, Allschwil, 
Switzerland) and human aortic endothelial cells (HAEC; Clonetics) were cultured as 
described.24 Protein expression was determined by Western blot analysis and RNA 
by real-time polymerase chain reaction (PCR). 
 
Tissue factor activity  
Factor Xa generation on the surface of VSMC, HAEC, or in tissues was 
analyzed using a colorimetric assay (American Diagnostica Inc, ACTICHROME).  
 
TF promoter activity 
TF promoter activity was measured as described.28 A minimal TF promoter (-
227 bp to +121 bp) was cloned upstream of the firefly luciferase reporter gene and a 
recombinant adenoviral vector was constructed. HAEC were transduced with the 
vector Ad5/hTF/Luc (100 pfu/cell) for 1 hour. An adenoviral vector without reporter 
gene (VQAd/Empty) was used as a negative control. After transduction, HAEC were 
grown in medium (10% FBS) for 24 hours and then serum-starved for 24 hours prior 
to TNF-α stimulation with or without ALA (30 µM) pretreatment. Firefly luciferase 
  
activity was determined by luminometer (Berthold Technologies, Bad Wildbad, 
Germany) and normalized to the protein concentration in the lysates. 
 
Nuclear extracts and NFkB activity  
Nuclear extracts were obtained from HAEC or mouse aorta using a nuclear 
extraction kit (Active Motif, Carlsbad, USA) and NFκB activity measured using a 
TransAM NFκB p65 kit (Active Motif). 
 
Statistics 
Data are presented as mean±SEM. Statistics were performed using the 
GraphPad prism 4.0 Software (GraphPad Software Inc., La Jolla, CA, USA). 
Statistical analysis was performed using 2-tailed unpaired Student´s t-test or one-way 
ANOVA as appropriate. A value of p<0.05 was considered significant.  
  
Results 
 
Dietary ALA inhibits arterial thrombosis 
C57BL/6 mice were fed for 2 weeks a 0.21% cholesterol diet containing either 7.3% 
w/w ALA (high ALA, treated group) or 0.03% w/w ALA (low ALA, control group). No 
difference in body weight was observed after 2 weeks of diet (n=7; p=NS; data not 
shown). Aorta from animals fed a high ALA diet showed markedly increased ALA 
levels (14.9% of total FA content; supplemental table 2) as compared to tissue from 
control animals (0.14% of total FA content; supplemental table 2). In contrast, EPA 
and DHA levels did not differ between the two groups. Total cholesterol levels were 
not altered (control: 2.27±0.17 mmol/l; low ALA: 1.95±0.21 mmol/l; high ALA: 
2.29±0.30 mmol/l; n=8; p=NS). 
Mice on control diet developed carotid artery thrombosis within a mean occlusion 
time of 40±4.2 minutes, while mice on high ALA diet occluded after 68±6 minutes 
(n=7; p<0.005; figure 1A). Initial blood flow did not differ between the two groups 
(n=7; p=NS). Intravenous administration of an inhibitory anti-TF antibody before the 
onset of photochemical injury reduced the difference in occlusion times between 
control and high ALA diet (n≥7; p=NS; figure 1B). Plasma clotting times (PT and 
aPTT) were similar in the two groups (PT: 11.1±0.2 seconds [low ALA] versus 
11.5±0.4 seconds [high ALA]; n=7; p=NS; aPTT: 20.3±0.8 seconds [low ALA] versus 
21.1±0.7 seconds [high ALA]; n=7; p=NS). Thrombin generation (endogenous 
thrombin potential [ETP] and time to peak [TTP]) did not differ between the groups 
(ETP: 747±94 nM/minute [low ALA] versus 818±80 nM/minute [high ALA]; n=5; 
p=NS; TTP: 6.2±0.7 minutes [low ALA] versus 4.8±0.5 minutes [high ALA]; n=5; 
p=NS). Further no difference in peak thrombin values (104.4±28.7 nM [low ALA] 
versus 118.8±22.9 nM [high ALA]; n=5; p=NS) nor in lag times (2.9±1.36 minutes 
  
[low ALA] versus 2.1±1.3 minutes [high ALA]; n=5; p=NS) was observed between the 
groups.  
To analyse differences in thrombus composition, sections from occluded 
carotid arteries were stained for TF, fibrin, and platelets. Although thrombi were 
occlusive in both groups, TF staining of in the vascular media was lower in the high 
ALA group as compared to the control group (figure 1C; n=4). In contrast, fibrin 
staining was similar in thrombi from both groups. Analysis of platelet content by 
immunhistochemistry for CD41 demonstrated a reduced platelet content in thrombi in 
the ALA treated group as compared to control (figure 1D; n=4). 
 
Dietary ALA inhibits platelet aggregation  
Thrombin induced platelet aggregation (figure 2A-D) was inhibited in mice fed 
a high ALA diet as compared to control platelets (maximal aggregation: n=5, 
p<0.005, figure 2B; area under the curve: n=5; p<0.005, figure 2C; lag time: n=5, 
p<0.05, figure 2D). When aggregation was induced by collagen, a similar inhibition 
was observed (maximal aggregation: n=5, p<0.005, figure 2F; area under the curve: 
n=5, p<0.05, figure 2G; lag time: n=5, p=0.14, figure 2H). Platelet number did not 
differ significantly between the groups (1062±46x103/µL [low ALA] versus 
911±5x103/µL [high ALA]; n=5; p=NS). 
Treatment of human platelets with ALA (30 µM) for 30 minutes ex vivo exerted 
a similar inhibition of thrombin and collagen induced platelet aggregation (n=5; 
supplemental table 3A-B). ALA (30 µM) impaired collagen and thrombin induced p38 
phosphorylation (n=3; p<0.01 versus collagen or thrombin alone; supplemental figure 
1A-B). 
 
Dietary ALA inhibits TF expression and NFκB activation 
  
TF activity in carotid arteries was markedly decreased in mice fed a high ALA 
diet as compared to controls (n=7; p<0.005, figure 3A). Inhibition of TF with a specific 
antibody confirmed that factor Xa generation was TF dependent (figure 3B). This 
decrease in TF activity was paralleled by an impaired TF mRNA expression in aortic 
tissue (n=7; p<0.01; figure 3C). In contrast, expression of tissue factor pathway 
inhibitor (TFPI) mRNA did not differ (ΔΔCt: 0.03±0.04 low ALA group versus 
0.03±0.04 high ALA; n=5; p=NS). NFκB p65 DNA binding affinity was measured in 
nuclear extracts from aortic tissue. NFκB activity was impaired in mice fed a high 
ALA diet as compared to controls (OD 490 nm: 0.97±0.02 [low ALA] versus 
0.70±0.09 [high ALA]; n=7; p<0.05, figure 3D). 
 
ALA inhibits TF protein expression in VSMC 
Treatment with ALA (30 µM) for 24 hours reduced TF expression in VSMC by 
46% (n=4; p<0.05) as compared to control (figure 4A). Real time PCR analysis 
confirmed that ALA inhibited TF expression in VSMC at the transcriptional level (n=4; 
p<0.005; figure 4B). In line with this observation, ALA decreased TF activity in VSMC 
(n=4; p<0.001; figure 4C). Experiments performed with an inhibitory anti-TF antibody 
confirmed that factor Xa generation in VSMC was TF dependent (figure 4D). TF 
expression was neither affected by the n-6 FA alpha-linoleic acid (LA) nor the 
saturated FA stearic acid (SA) (n=4; p=NS; data not shown). No cytotoxic effects of 
ALA, LA, or SA in VSMC were observed for any of the concentrations (data not 
shown).  
 
ALA inhibits p38 phosphorylation and NFkB activity in VSMC 
Analysis of the MAP kinase phosphorylation demonstrated that treatment of 
VSMC with ALA for 24 hours resulted in a significant decrease in p38 activation 
  
(49±14% inhibition; n=4; p<0.05; figure 5A). In contrast, activation of JNK and ERK 
remained unaffected. Blockade of the MAP kinase p38 with SB203580 (10 µM)  
inhibited TF expression in VSMC (n=4; p<0.01; figure 5B). Treatment with ALA (30 
µM) reduced NFκB p65 DNA binding affinity in nuclear extracts from VSMC (n=4; 
p<0.05; figure 5C). 
 
ALA inhibits TNF-α induced TF mRNA expression via MAP kinase and 
ASK1 in HAEC 
HAEC were treated with ALA or vehicle for 1 hour and then stimulated with 
TNF-α (5 ng/mL) for 4 hours. ALA inhibited TNF-α induced endothelial TF expression 
in a concentration dependent manner with a maximal effect at 30 µM (86% inhibition; 
n=5; p<0.001 versus TNF-α alone; figure 6A). In line with this observation, ALA 
decreased TF activity in HAEC (51% inhibition versus TNF-α alone; n=4; p<0.001; 
figure 6B).  
Real-time PCR analysis demonstrated that ALA (30 µM) inhibited TNF-α 
induced endothelial TF mRNA expression (n=4; p<0.001; Figure 6C). This decrease 
in TF mRNA was paralleled by an impaired activation of the MAP kinases JNK, p38, 
and ERK (28%, 62%, and 55% inhibition versus TNF-α alone, respectively; n=4; 
p<0.05; figure 6D). Consistent with this pattern of MAP kinase inhibition, ALA 
impaired activity of the MAPKKK ASK1 (n=3; p<0.005 versus TNF-α alone; figure 
6E). ALA (30 µM) inhibited TNF-α induced TF promoter activation in HAEC by 47% 
(n=4; p<0.05, figure 6F). ALA (30 µM) blunted TNF-α induced IκB-α degradation 
(n=3; p<0.05). This effect was paralleled by reduced DNA binding activity of the 
NFκB subunit p65 (54% inhibition versus TNF-α alone, n=4; p<0.01). To confirm the 
involvement of NFκB in TNF-α induced endothelial TF expression, the effect of 
different NFκB inhibitors was assessed. Both BAY 11-7082 (5 µM) and PDTC (10 
  
µM) inhibited TNF-α induced TF expression (-66% and -47% versus TNF-α alone, 
respectively; n=4; p<0.01). 
 
Discussion 
 
Variations of the dietary n-3/n-6 ratio have been reported to affect the 
susceptibility to thrombosis in atherosclerotic mice.29 However, it remains unknown 
whether ALA can exert such an effect and whether if influence thrombosis directly or 
via other PUFA. 
The present study demonstrates that dietary supplementation with ALA for 2 
weeks impaired arterial thrombus formation, platelet activation, TF activity, and NFκB 
activity in mice in vivo. The ALA rich diet increased tissue levels of ALA, while there 
was no significant change in tissue levels of the long chain n-3 FA EPA and DHA. 
Consistent with these findings, ALA by itself impaired platelet aggregation and TF 
induction in different human primary cells cultures. This effect occurred at the 
transcriptional level involving inhibition of MAP kinase phosphorylation, NFκB 
activation, and promoter activation.  
The ALA concentrations used for experiments in this study are in a clinically 
relevant range. Indeed, baseline plasma levels of ALA have been reported to range 
from 17-19 µM, whereas a daily oral ingestion of 3 g ALA leads to ALA plasma levels 
of 32±17 µM and is well tolerated15. Dietary supplementation of ALA for 2 weeks was 
sufficient to markedly increase the ALA levels in the aortic wall, whereas EPA and 
DHA levels did not differ from the control group. The lack of a measurable conversion 
to long chain n-3 FA is in line with previous epidemiological studies demonstrating 
that dietary ALA poorly correlates with EPA and DHA levels in adipose tissue, 
erythrocytes or plasma16. Even more important, the in vivo effects of dietary ALA 
  
observed in the present study were mimicked by exogenous ALA in both human 
platelets and vascular cells ex vivo, where hepatic conversion of ALA to EPA and 
DHA does not occur. Taken together, these experiments indicate that the anti-
thrombotic effects of ALA in vivo did not depend on the conversion of ALA to long 
chain n-3 FA and provide strong evidence for a direct biological effect of ALA.  
To exclude possible effects of other FA, control experiments were performed 
with the n-6 FA linoleic acid as well as the saturated FA stearic acid. Neither of these 
FA altered TF expression, supporting the interpretation that the biological effects of 
the high ALA diet on TF and thrombosis occur due to the increased ALA levels. 
 Dietary ALA supplementation significantly delayed arterial thrombus formation 
triggered by photochemical injury in vivo. Since this effect was paralleled by a 
reduced platelet activation and a diminished arterial TF activity, ALA impairs 
thrombus formation by a dual action on both critical events involved in arterial 
thrombosis following vascular injury. In order to determine the relative contribution of 
platelets and TF to thrombus formation, an inhibitory anti-TF antibody was applied. 
Treatment with this antibody reduced the difference in occlusion times between the 
two groups, suggesting that the inhibitory effect of ALA on TF exerts a major effect 
on thrombus formation, while its effect on pletelets contributes to inhibition of 
thrombosis. These results support previous observations demonstrating that arterial 
thrombosis is primarly driven by TF derived from the vessel wall in this model.30,31 TF 
is barely expressed under basal conditions in endothelial cells, while it is 
constitutively expressed in VSMC.32 Immunohistochemical analysis confirmed that TF 
expression in the arterial tunica media was decreased in carotid arteries derived from 
the ALA treated group. Inhibition of TF was confirmed in vivo, since the ALA rich diet 
decreased TF expression and NFkB activity in arterial lysates. Consistent with these 
in vivo observation, treatment of VSMC with ALA for 24 hours decreased basal TF 
  
expression. This effect was mediated at the transcriptional level via the MAP kinase 
p38. Pharmacological inhibition of p38 confirmed the crucial role of p38 activation in 
constitutive TF expression in VSMC. In line with p38 inhibition as well as with 
previous data obtained in monocytes and macrophages ALA also reduced  NFkB 
activity in VSMC.33,34 Hence, direct inhibition of TF in VSMC via p38 and NFkB 
seems to play a major role in ALA’s effect on arterial thrombus formation. 
In order to study whether ALA also affects inducible TF expression, additional 
experiments were performed in cytokine activated endothelial cells. TNF-α induced 
endothelial TF expression is mediated through activation of MAP kinases leading to 
activation of transcription factors such as AP-1 and EGR-1, whereas the IκB kinase 
pathway promotes NFκB activation.35,36 ASK1 is a redox regulated kinase playing an 
essential role in stress induced activation of MAP kinases, thus triggering various 
cellular processes including inflammatory responses and TF expression.32,37 In 
endothelial cells, TNF-α has been shown to activate ASK1 as well as MAP 
kinases.6,37 Treatment with ALA significantly reduced phosphorylation of the MAP 
kinases p38, JNK, and ERK in endothelial cells. Consistent with the inhibition of MAP 
kinase phosphorylation, ALA also prevented activation of ASK1. Thus, it is likely that 
ASK1 represents a common upstream target of ALA disrupting the MAP kinase 
signalling pathway in endothelial cells. 
Immunohistochemical analysis of CD41 (platelet glycoprotein IIb) expression 
demonstrated that thrombi contained less platelets in the ALA treated group as 
compared to the control group. Platelet aggregation was analyzed using collagen and 
thrombin as agonists, since they play a dominant role in platelet activation following 
vascular injury.3 ALA impaired both collagen and thrombin induced platelet 
aggregation, indicating that ALA inhibits glycoprotein VI and Ib-V-IX as well as 
protease-activated receptor mediated platelet activation; hence, ALA does not 
  
interfere with activation of a single pathway. Since the MAP kinase p38 plays a 
crucial role in collagen as well as thrombin induced platelet activation and adhesion, 
the effect of ALA on p38 phosphorylation in isolated platelets was investigated.38,39 
ALA decreased collagen and thrombin induced p38 activation, an effect that may well 
account for the reduced aggregation observed in ALA treated platelets. Taken 
together, these observations may provide an explanation for the remaining difference 
in occlusion times observed between the two groups after treatment with an inhibitory 
anti-TF antibody. 
In summary, this study provides solid evidence for a potent dual anti-
thrombotic effect of an ALA rich diet by reducing platelet activation and impairing 
vascular TF expression. These effects were reproduced in a mouse model as well as 
in human primary cell cultures and were not related to an increase in EPA and DHA 
levels as confirmed by our data. Hence, this study generates pathophysiological 
evidence for direct anti-thrombotic effects of dietary ALA supplementation. Since the 
limited availability or unfavourable geographic conditions restrict the access to n-3 FA 
from marine origin in many countries, plant-derived ALA might therefore represent an 
attractive cardioprotective alternative. However, keeping in mind previous clinical 
setbacks with experimentally promising nutritional compounds such as vitamin E, 
there is a great need for placebo-controlled randomized large-scale clinical trials to 
confirm the long-term anti-thrombotic potential of dietary supplemented ALA. 
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Figure Legends 
 
Figure 1. Dietary ALA inhibits arterial thrombus formation.  
A. Dietary ALA impairs time to thrombotic occlusion after photochemical injury in the 
mouse carotid artery in vivo (*p<0.005). B. Treatment with an inhibitory anti-TF 
antibody blunts the difference in occlusion times (p=NS). C. Sections of thrombosed 
carotid artery (L: vessel lumen, M: vessel media) from control and ALA treated 
animals (n=4) were stained for TF and fibrin (brown stain). Scale bars equal 50 µm; 
HE: hematoxylin and eosin stain. D. Sections from occluded carotid arteries were 
also stained for CD41 (red stain) and nuclei (blue stain). Scale bars equal 100 µm. 
HE: hematoxylin and eosin stain. 
 
Figure 2. Dietary ALA inhibits platelet aggregation. 
Thrombin (A) and collagen (E) induced platelet activation is inhibited in mice fed a 
high ALA diet as compared to control animals. Dietary ALA reduced maximal 
aggregation (B. thrombin: *p<0.005; F. collagen: *p<0.005), reduced area under the 
curve (C. thrombin: *p<0.005; G. collagen: *p<0.05), and increased lag time (D. 
thrombin: *p<0.05; H. collagen: p=NS). 
 
Figure 3. Dietary ALA inhibits TF expression and NFκB activity in vivo. 
Dietary ALA inhibits TF activity as assessed by FXa generation in carotid arteries (A. 
*p<0.005). B. Treatment of tissue lysates with an inhibitory anti-TF antibody (10 
mg/ml) inhibits FXa generation (*p<0.01 versus control diet group in the presence of 
an IgG control antibody). Dietary ALA impairs TF mRNA expression (C. *p<0.05), 
  
and NFkB p65 DNA binding affinity (D. *p<0.05) in mouse carotid arteries.  
 
Figure 4. ALA inhibits TF expression in VSMC. 
A. Treatment with ALA (30 µM) for 24h inhibits TF protein expression in VSMC 
(*p<0.05 versus control). B. ALA (30 µM) inhibits TF mRNA expression (*p<0.005 
versus control) after 24h. C. ALA (30 µM) also impairs TF activity in VSMC 
(*p<0.001). D. Treatment of VSMC with an inhibitory anti-TF antibody inhibits FXa 
generation (*p<0.05 versus control treated with an IgG control antibody).  
 
Figure 5. ALA inhibits p38 activation and NFkB activity in VSMC. 
A. Treatment with ALA (30 µM) for 24h decreases p38 activation in VSMC  (*p<0.05 
versus control). B. Inhibition of p38 with SB203580 (10 µM) for 24h impairs TF 
expression in VSMC (*p<0.01 versus control). C. ALA (30 µM) reduces DNA binding 
activity of the NFκB subunit p65 in VSMC (*p<0.05 versus control). 
 
Figure 6. ALA inhibits TNF-α induced TF expression in HAEC 
A. Treatment with ALA (10-30 µM) for 1h inhibits TNF-α induced TF protein 
expression in human endothelial cells (*p<0.01 versus TNF-α alone). B. ALA  (30 
µM) inhibits TNF-α induced endothelial TF surface activity (*p<0.001 versus TNF-α 
alone). C. ALA (30 µM) inhibits TNF-α induced endothelial TF mRNA expression 
(*p<0.001 versus TNF-α alone). D. Incubation with ALA (30 µM) for 1h inhibits TNF-α 
induced transient phosphorylation of JNK, p38, and ERK. E. ALA (30 µM) inhibits 
TNF-α induced ASK1 phosphorylation  (*p<0.005 versus TNF-α alone). F. ALA (30 
µM) impairs endothelial TF promoter activation (*p<0.05 versus TNF-α alone).  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Supplemental figure I. ALA inhibits thrombin and collagen induced p38 
activation in platelets. 
A. ALA (30 µM) abrogates thrombin induced p38 phosphorylation (*p<0.01 versus 
thrombin alone). B. ALA inhibits collagen induced p38 phosphorylation (*p<0.01 
versus collagen alone). 
 
 
  
Supplement Material 
 
Material and methods 
ALA diet and carotid artery thrombosis model  
8-week-old male C57BL/6 mice weighing on average 24 g were fed a 0.21% 
w/w cholesterol diet containing either a high ALA (7.3% w/w , D06080702, Research 
Diets, New Brunswick, NJ, USA) or low ALA concentration (0.03% w/w, D06080701, 
Research Diets) for 2 weeks (supplemental table 1). ALA was supplemented as 
flaxseed oil in the high ALA group and replaced by cocoa butter in the control group. 
Thrombus formation was induced by photochemical injury on the 14th day of diet. 
Mice were anesthetized by intraperitoneal injection of sodium pentobarbital (87 
mg/kg; Butler, Columbus, OH). Rose bengal (Fisher Scientific, Fair Lawn, NJ, USA) 
was diluted in phosphate-buffered saline (PBS) and then injected into the tail vein at 
a final concentration of 50 mg/kg. The right common carotid artery was exposed 
following a midline cervical incision and the blood flow monitored using a Doppler 
flow probe (Model 0.5 VB, Transonic Systems, Ithaca, NY) connected to a flowmeter 
(Model T106, Transonic Systems). Photochemical injury was induced by a 1.5 mW 
green light laser (540 nm; Melles Griot, Carlsbad, CA) 6 minutes after intravenous 
rose bengal injection. From the onset of injury, blood flow was monitored until 
occlusion occurred, which was defined as a flow below 0.1 ml/min for at least 1 
minute. Where mentioned, an inhibitory mouse anti-TF antibody obtained by 
immunization of rabbits against the extracellular murine TF amino acid domain 29-
250 (American Diagnostica Inc., Stamford, CA, No. 4515,) was injected intravenously 
at a concentration of 3 mg/kg body weight 20 minutes prior to the rose bengal 
injection. 
 
  
Immunohistochemistry 
 Occluded carotid arteries were harvested, fixed in 3% formalin and embedded 
in paraffin. Sections were stained for platelets (anti–mouse CD41; Abcam, 
Cambridge, UK; 1:50 dilution), fibrin (Anti-human, fibrin Fragment E, Cedarlane, 
Burlington, ON, Canada; 1:100 dilution) and TF (American Diagnostica; 1:50 dilution). 
Slides were blocked with 10% goat serum, and the primary antibody applied 
overnight at 4°C. Immunodetection was performed using biotinylated rabbit anti–
mouse (for fibrin and TF, 1:200 dilution), or Texas red conjugated goat anti-rat 
secondary antibodies (1:200 dilution). Slides were counterstained with hematoxylin 
and eosin (TF and fibrin) or 4',6-diamidino-2-phenylindole (CD41) . 
 
Platelet preparation 
For analysis of p38 expression, citrated whole blood was centrifuged at 170xg 
for 7 minutes to obtain platelet-rich plasma (PRP). PRP was centrifuged a second 
time at 170xg for 7 minutes to remove residual erythrocytes. To isolate platelets PRP 
was centrifuged at 350xg. Pelleted platelets were resuspended in tyrode buffer (10 
mM Hepes, 12 mM NaHCO3,137 mM NaCl, 2.7 mM KCl, 5 mM glucose; pH 7.4) and 
incubated with thrombin or collagen in the presence of ALA (30 µM) or the vehicle for 
various time points. Reactions were stopped by addition of ice-cold lysis buffer and 
p38 phosphorylation assessed by western blot analysis as described below. 
 
Platelet count and aggregation 
Platelets were counted by flow cytometry using whole blood collected in EDTA 
tubes (B&D Diagnostics, Franklin Lakes, NJ, USA). Platelet aggregation was studied 
using a Chrono-Log whole blood impedance aggregometer (Chrono-Log, Havertown, 
PA, USA). For studies performed in murine platelets, citrated blood was drawn by 
  
puncture from the right ventricle. For studies in human platelets, blood was obtained 
from healthy human volunteers and treated with ALA (30 μM; Cayman Chemical, Ann 
Arbor, MI, USA) or vehicle (ethanol 0.1%, Sigma Aldrich, St. Louis, USA) for 30 
minutes. Aggregation studies were performed with citrated blood within 1 hour. 
Platelets were equilibrated under constant stirring for 1 minute prior addition of 
human thrombin (0.5 U/mL; Sigma Aldrich) or equine collagen type 1 (5 µg/mL; 
Chrono-Log). Aggregation was displayed as a function of time (AGGRO/LINK® 
Software; Chrono-Log). Results were monitored for 6 minutes and expressed as 
maximal aggregation (ohm[Ω]), area under the curve (Ωxmin), and lag time 
(seconds).  
 
Fatty acid profile in aortic tissue 
Aortic tissue was pooled (n=7 per group) and FA profiles of the tissues were 
analyzed by gas chromatography. Fat was extracted via hexane:isopropanol (3:2) 
and triglycerides were saponified using methanolic sodium hydroxide. FA were 
converted to fatty acid methyl ester (FAME) with methanolic boron trifluoride. FAME 
were separated using a gas chromatograph (Hewlett Packard HP 6890 Series, GC 
Systems, Waldbronn, Germany) equipped with a 200 mm x 0,25 mm CP7421-
column (Varian, Middleburg, NL). For FAME identification, a FAME mixture was used 
as external standard (Supelco 37 component FAME mix). The proportion of different 
FAME was calculated using the ratio of the peak area of the respective FAME to the 
sum of total FAME peak areas. FA were evaluated using the HP ChemStation 
software (Hewlett Packard, CA, USA). Measurements were performed in duplicate 
and the mean value displayed.  
 
Prothrombin time (PT) and activated partial thromboplastin time (aPTT) 
  
Plasma was isolated from citrated blood (3.2%; 1/10) by centrifugation (2500xg; 
4°C; 15 minutes). PT and aPTT were assessed using the START 4 analyzer 
(Diagnostica Stago, France). 
 
Thrombin generation 
Plasma thrombin generation was monitored by automated calibrated 
thrombography.1 Platelet poor plasma was mixed with human recombinant TF (5 pM) 
and a fluorogenic substrate for thrombin (Z-Gly-Gly-Arg-AMC Bachem Basle, 
Switzerland) and then recalcified. Thrombin generation was measured in a 
Fluoroskan® Ascent reader (Thermo Labsystems, Helsinki, Finland) and calculated 
using the Thrombinoscope software (Thrombinoscope BV, Maastricht, The 
Netherlands). Endogenous thrombin potential, representing the area under the 
thrombin generation curve and time to peak thrombin formation (TTP) were displayed 
using the Prism 4 software package (GraphPad Software Inc., La Jolla, USA). 
 
Cell culture 
Human aortic vascular smooth muscle cells (VSMC; Clonetics, Allschwil, 
Switzerland) and human aortic endothelial cells (HAEC; Clonetics) were cultured as 
described.2 For experiments, VSMC were serum-starved for 24 hours before 
pretreatment with ALA (Cayman Chemical, Ann Arbor, MI, USA), stearic acid (SA, 
Sigma Aldrich), linoleic acid (LA, Sigma Aldrich) or vehicle (ethanol 0.1%, Sigma 
Aldrich) for 6 or 24 hours. To block the mitogen-activated protein (MAP) kinase p38 
MAP kinase (p38), VSMC were treated with SB203580 (Sigma Aldrich; 10) for 24 
hours. For experiments with HAEC, cells were incubated with ALA for 1 hour prior 
stimulation with 5 ng/mL TNF-α (R&D Systems, Minneapolis, MN) for 4 hours for 
protein expression analysis and for 2h for analysis of TF mRNA expression. NFκB 
  
activation was inhibited by ammonium pyrrolidinedithiocarbamate (PDTC) or BAY 11-
7082 (both from Sigma Aldrich) pretreatment for 24 hours. To determine cytotoxicity, 
a colorimetric assay for detection of lactate dehydrogenase release was applied 
(Roche, Basel, Switzerland).  
 
Western blot 
Protein expressionin was determined by Western blot analysis. Antibodies 
against human TF (No. 4503) and tissue factor pathway inhibitor (TFPI, No. 4901) 
(both from American Diagnostica, Stamford, CT) were used at 1:2500 dilution. 
Antibodies against phosphorylated p38, ERK, JNK, and ASK1 (all from Cell 
Signaling) were used at 1:1000, 1:5000, 1:2000, and 1:2000 dilution, respectively. 
Antibodies against total p38, ERK, JNK, and ASK1 (all from Cell Signaling, Danvers, 
MA) were used at 1:2000, 1:5000, 1:2000, and 1:2000 dilution, respectively. Blots 
were normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
expression (1:10000 dilution, Chemicon International, Temecula, CA).  
 
Factor Xa generation 
To assess TF activity factor Xa generation on the surface of VSMC and HAEC 
was analyzed using a colorimetric assay (American Diagnostica Inc, ACTICHROME). 
TF/FVIIa complex converted human factor X to factor Xa, which was measured by its 
ability to metabolize a chromogenic substrate. The absorbance of the reaction 
mixture was measured at 405 nm and values displayed after substraction of the 
background value. To confirm TF dependency of factor Xa generation in VSMC, cells 
were incubated with an inhibitory anti-TF antibody (American Diagnostica, No. 4509; 
1:200) 30 minutes prior addition of exogenous factor VIIa.  
For analysis of factor Xa generation in mouse carotid arteries, occluded right 
  
carotid arteries from treated and control mice were homogenized in 50 µL lysis buffer 
(0.1% Triton-X, 100 mmol Nacl, 50 mmol Tris-Hcl, pH 7.4). 25 µg of tissue lysates 
were used for measurements. TF dependency of factor Xa generation in tissue 
lysates was confirmed by incubation with an inhibitory mouse anti-TF antibody 
(American Diagnostica; No. 4515; 10 mg/ml) 30 minutes prior addition of exogenous 
factor VIIa. 
 
Real Time PCR 
RNA was extracted from VSMC, HAEC and mouse aorta using TRIzol 
Reagent (Invitrogen, Carlsbad, CA) and reverse transcribed using Ready-To-Go 
You-Prime First-Strand Beads (Amersham, Buckinghamshire, UK). For real-time 
PCR analysis the following primers were used: for full length human TF (F3): sense 
5’-TCCCCAGAGTTCACACCTTACC–3’, antisense 5’–
CCTTTCTCCTGGCCCATACAC–3’; for human ribosomal L28: sense 5’-
GCATCTGCAATGGATGGT-3’, antisense 5′-TGTTCTTGCGGATCATGTGT-3′; for 
murine full length tissue factor: sense: 5'-CAATGAATTCTCGATTGATGTGG-3', 
antisense: 5'-GGAGGATGATAAAGATGGTGGC-3'; for murine tissue factor pathway 
inhibitor: sense: 5'-ACTGTGTGTCTGTTGCTTAGCC-3', antisense: 5'-
GTTCTCGTTCCCTTCACATCCC3'; and for murine ribosomal S12: sense: 5'-
GAAGCTGCCAAAGCCTTAGA-3', antisense: 5'-AACTGCAACC-AACCACCTTC-3'. 
The amplification program consisted of 1 cycle at 95°C for 10 minutes followed by 35 
cycles with a denaturing phase at 95°C for 30 seconds, an annealing phase at 60°C 
for 1 minute, and an elongation phase at 72° for 1 minute. Melting curve analysis 
confirmed the accuracy of the amplicon, and PCR products were analyzed on an 
ethidium bromide stained 1% agarose gel. In each real-time PCR run for human TF 
and L28, a standard curve generated from serial dilutions of purified amplicons was 
  
included. For murine TF and S12 the ΔΔCt threshold cycle method was used. 
 
Nuclear Extracts and NFκB activity  
For measurement of NFkB activity, VSMC were treated with ALA (30 µM)  or 
the vehicle for 24 hours. Nuclear extracts were obtained from VSMC or mouse aorta 
using a nuclear extraction kit (Active Motif, Carlsbad, USA). Total protein (20 µg) was 
loaded in each well, and NFκB activity was measured using a TransAM NFκB p65 kit 
(Active Motif). 
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Abstract  
 
Background. Tissue factor (TF) is an important trigger of arterial thrombosis. The 
green tea catechin epigallocatechin-3-gallate (EGCG) is a ligand of the 67 kDa 
laminin receptor (67LR) and exhibits cardioprotective effects. This study investigates 
whether 67LR regulates TF expression in human endothelial cells. 
Methods and Results. Immunofluorescence demonstrated that human aortic 
endothelial cells expressed 67LR. Cells grown on laminin expressed 35% less TF in 
response to TNF-alpha (TNF-α) than those grown on fibronectin (n=6; p<0.001). 
EGCG (1-30 µM) inhibited TNF-α and histamine induced endothelial TF expression 
and activity in a concentration dependent manner resulting in 87% reduction of TF 
expression (n=5; p<0.001); in contrast, expression of tissue factor pathway inhibitor 
was not affected (n=4; p=NS). In vivo administration of EGCG (30 mg/kg/d) inhibited 
TF activity in carotid arteries of C57BL6 mice. Real-time PCR and promoter studies 
revealed that EGCG decreased TF expression at the transcriptional level and 
impaired activation of the mitogen activated protein (MAP) kinase JNK 1/2, but not 
ERK or p38.  Similarly, the JNK 1/2 inhibitor SP600125 (1 µM) impaired TF promoter 
activity (n=4; p<0.001) and protein expression (n=4; p<0.001). 67LR blocking 
antibodies blunted the inhibitory effect of EGCG on both TF protein expression and 
JNK activation. In contrast, vascular cell adhesion molecule 1 (VCAM-1) was not 
affected by laminin nor EGCG, and its expression was not regulated by JNK. EGCG 
did not affect TNF-α stimulated NFkB activation. 
Conclusions. Laminin receptor activation inhibits endothelial TF expression by 
impairing JNK phosphorylation. Thus, 67LR may be a potential target for the 
development of novel anti-thrombotic therapies.  
  
Introduction 
 
Tissue factor (TF) plays an important role in initiating coagulation [1]. 
Inflammatory mediators such as TNF-alpha (TNF-α) or histamine are potent inducers 
of TF expression in vascular cells [2]. Elevated levels of TF are detected in 
atherosclerotic plaques, and an involvement of TF in drug-eluting stent thrombosis 
has been discussed as well [3,4]. These findings suggest that modulation of TF 
expression in vascular cells may offer a strategy for the treatment and prevention of 
arterial thrombosis. 
The extracellular matrix (ECM) plays a pivotal role in vascular homeostasis, 
since it maintains vascular integrity by regulating proliferation, migration, and 
morphogenesis of endothelial cells [5,6]. Indeed, the basement membrane forms a 
scaffold around the endothelial tube, and interactions between endothelial cells and 
constituents of the basement membrane are essential for vessel wall integrity [7]. 
The non-collagenous glycoprotein laminin is a cross shaped heterotrimer of α, β, and 
γ subunits and a major component of the basement membrane [7]. The membrane 
bound 67 kDa-laminin receptor (67LR) is a non-integrin cell surface receptor directly 
interacting with the β1 subunit of laminin [8]. Besides its role in cell adherence to the 
extracellular matrix, there is growing evidence that 67LR activation induces functional 
changes within cells [8]. 67LR has indeed been implicated in shear stress induced 
endothelial nitric oxide synthase (eNOS) activation, since its blockade abolished 
shear induced eNOS phosphorylation [9]. Despite such observations, the role of 
67LR in endothelial activation remains incompletely understood, and possible 
implications for arterial thrombosis have not been investigated.  
Recently, 67LR has been identified as a cell surface receptor for the green tea 
polyphenol epigallocatechin-3-gallate (EGCG) [10]. EGCG is the most abundant 
  
polyphenol found in green tea and constitutes 30% of its dry mass. Experimental 
studies revealed cardioprotective properties of ECGC consisting in anti-inflammatory, 
anti-oxidant, and anti-atherogenic effects [11-16]; moreover, large epidemiological 
trials demonstrated that green tea consumption is inversely associated with 
cardiovascular mortality [17-19]. 
The present study investigates whether 67LR modulates TF expression in 
human aortic endothelial cells.  
  
Methods 
 
Cell culture 
Human aortic endothelial cells (HAEC; Clonetics, Allschwil, Switzerland), 
human umbilical venous endothelial cells (HUVEC; Clonetics) and human aortic 
vascular smooth muscle cells (HASMC, Clonetics) were cultured on fibronectin as 
described [20]. Cells were rendered quiescent in medium supplemented with 0.5% 
fetal bovine serum for 24 hours before stimulation with 5 ng/mL TNF-α (R&D 
Systems, Minneapolis, MN) or 10 µM histamine (Sigma, St. Louis, MO). Cells were 
pretreated with EGCG (Sigma) for 60 minutes. For studies of VCAM-1 and TF protein 
expression HAEC were stimulated for 5 hours. To block the mitogen activated protein 
(MAP) kinase c-Jun terminal NH2 kinase 1/2 (JNK 1/2), HAEC were treated with 
SP600125 (Calbiochem, Lucerne, Switzerland) for 60 minutes before stimulation. 
Cytotoxicity was assessed using a colorimetric assay for detection of lactate 
dehydrogenase release (Roche, Basel, Switzerland). Where mentioned, dishes were 
coated with laminin (25 µg/mL; Sigma). To compensate for the slower growth rates of 
HAEC on laminin as compared to fibronectin, a higher cell number was seeded on 
the dishes; the two groups exhibited similar confluency at the time of the 
experiments. To study the role of 67LR, cells were pretreated for 60 minutes with 
either a monoclonal (MLuC5, 1:1’000) or a polyclonal (ab711, 1:1’000) anti-human 
67LR blocking antibody or the appropriate isotype antibodies (all from Abcam, 
Cambridge, UK).  
 
Immunofluorescence microscopy 
HAEC were grown on LabTek chamber slides (Nunc, Rochester, MN), washed 
  
three times with PBS, and fixed with 4% paraformaldehyde for 15 min. Cells were 
washed twice with PBS and incubated with anti-67LR (MLuC5) antibody for 1 hour 
(1:1’000), followed by incubation with Alexa-488 conjugated secondary antibody 
(Invitrogen, Carlsbad, CA) for 1 hour (1:2’000). Antibodies were diluted in PBS 
containing 1% bovine serum albumin. After washing with PBS, cells were 
counterstained with 4',6-diamidino-2-phenylindole (DAPI) (Vector Laboratories Inc., 
Burlingame, CA), mounted on chamber slides, and examined by a fluorescence 
microscope (Olympus, DP40, Tokyo; Japan).  
 
Western blot 
Protein expression was determined by Western blot analysis. Antibodies 
against human TF, tissue factor pathway inhibitor (TFPI) (both from American 
Diagnostica, Stamford, CT), and vascular cell adhesion molecule-1 (VCAM-1; R&D 
Systems, Minneapolis, MN) were used at 1:2500 dilution. Antibodies against 
phosphorylated p38 MAP kinase (p38), p44/42 MAP kinase (extracellular signal 
regulated kinase [ERK]), and c-Jun NH2 terminal kinase (JNK1/2; all from Cell 
Signaling, Danvers, MA) were used at 1:1000, 1:5000, and 1:1000 dilution, 
respectively. Antibodies against total p38, ERK, and JNK1/2 (all from Cell Signaling) 
were used at 1:2000, 1:5000, and 1:1000 dilution, respectively. IkB-α expression 
pattern was assessed by anti-human IkB-α antibody (1:5000; Cell Signaling). All blots 
were normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
expression (1:10’000 dilution, Chemicon International, Temecula, CA). The 
quantification of protein was performed by densitometric analysis using Scion Image 
Software (Scion Corp., Frederick, MD). 
 
TF surface activity 
  
TF surface activity was analyzed on HAEC after 5 hours of stimulation with 
TNF-α in the presence or absence of EGCG (30 µM) using a colorimetric assay 
(American Diagnostica). Briefly, TF/FVIIa complex converted human factor X to factor 
Xa, which was measured by its ability to metabolize a chromogenic substrate. The 
absorbance of the reaction mixture was measured at 405 nm, and TF activity was 
determined from a standard curve performed with lipidated human TF. 
 
In vivo study 
Analysis of TF activity was performed in 10 week old male C57BL6 mice 
(Jackson Laboratories, Bar Harbor, ME) weighing an average of 26 g and fed a 
normal chow diet (KLIBA NAFAG, Kaiseraugst, Switzerland). EGCG was dissolved in 
PBS (pH 7.4) and administrated i.p. at a dose of 30 mg/kg/d for 7 days. Age, sex, 
and weight matched controls received an equal volume of vehicle. Mice were then 
euthanized and the left common carotid artery harvested for analysis of TF activity 
using a colorimetric assay (American Diagnostica). 
 
Real-time PCR 
RNA was extracted from HAEC using TRIzol Reagent (Invitrogen, Carlsbad, 
CA) and real-time PCR performed as described [20]. The following primers were 
used: for full length human TF (F3): sense 5’-TCCCCAGAGTTCACACCTTACC–3’ 
(bases 508-529 of F3 cDNA; NCBI no. NM 001993), antisense 5’–
CCTTTCTCCTGGCCCATACAC–3’(bases 843-863 of F3 cDNA; NCBI no. NM 
001993); for human ribosomal L28: sense 5’-GCATCTGCAATGGATGGT-3’, 
antisense 5’–CCTTTCTCCTG-GCCCATACAC-3’. Melting curve analysis was 
performed after amplification to verify the accuracy of the amplicon, and PCR 
products were analyzed on an ethidium bromide stained 1% agarose gel. In each 
  
real-time PCR run for TF and L28, a standard curve generated from serial dilutions of 
purified amplicons was included.  
 
TF promoter activity 
TF promoter activity was measured as described [21]. Briefly, the minimal TF 
promoter (-227 bp to +121 bp) was cloned upstream of the firefly luciferase reporter 
gene using a pGL2-Basic plasmid (Promega, Madison, WI). For transduction, the 
adenoviral vector Ad5/hTF/Luc was added to HAEC at an multiplicity of infection of 
100 plaque forming units/cell for 1 hour and then removed. The adenoviral vector 
VQAd Empty was used as a negative control.  HAEC were kept in growth medium for 
24 hours and then serum starved for 24 hours prior to TNF-α stimulation for 1 hour 
with or without EGCG (30 µM). Firefly luciferase activity was determined in cell 
lysates using a luminometer (Berthold Technologies, Bad Wildbad, Germany) and 
normalized by determing protein concentration in the lysates. 
 
Transfection with siRNA 
HAEC were transfected with siRNA (15 nM) against JNK 1 (5’-
AAAGAAUGUCCUACCUUCUTT-3’), JNK 2 (5’-AGAAGGUAGGA-CAUUCUUUTT-
3’) or scrambled RNA (all from Sigma) using the N-TER™ Nanoparticle siRNA 
Transfection System (Sigma) for 4 hours. After transfection, HAEC were grown for 12 
hours and then serum starved for 24 hours prior to the experiment. 
 
Nuclear extraction and NFkB activity assay 
For NFκB activity measurements, HAEC were stimulated with TNF-α for 30 
minutes in the presence or absence of EGCG (30 µM). Nuclear extracts were 
obtained from HAEC using a nuclear extraction kit (Active Motif, Carlsbad, USA). 
  
Nuclear protein (20 µg) was loaded in each well, and NFκB activity was measured 
using a TransAM NFkB p65 kit (Active Motif) according to manufacturer’s 
recommendations. 
 
Statistics 
Data are presented as mean±SEM. Statistical analysis was performed using 
two tailed unpaired Student´s t-test or one-way ANOVA as appropriate. A value of 
p<0.05 was considered significant. All results are representative of at least four 
independent experiments. 
  
Results 
 
Laminin inhibits TF protein expression 
Immunofluorescence microscopy revealed that 67LR was abundantly 
expressed on the surface of HAEC (Figure 1A). Western blot analysis demonstrated 
that TNF-α (5ng/mL) induced TF expression was 35% lower in cells growing on 
laminin as compared to those growing on fibronectin (n=4; p<0.001; Figure 1B). 
 
67LR inhibits TF protein expression  
EGCG (1-30 µM) inhibited TNF-α (5 ng/mL) induced TF expression in a 
concentration dependent manner (n=5; *p<0.001; figure 2A); the maximal effect 
occurred at 30 µM and decreased TF expression by 87% as compared to TNF-α 
alone. Similarly, EGCG (30 µM) inhibited histamine (10 µM) induced TF expression 
by 84% as compared to histamine alone (n=5; *p<0.001; figure 2B). EGCG did not 
affect expression of TFPI (n=4; p=NS; supplemental figure 1). The effect of EGCG on 
TF protein expression was paralleled by a reduced TF surface activity (n=4; 
*p<0.001; figure 2C). Further the effect of EGCG on TF activity was assessed in 
carotid artery lysates of C57BL6 mice. EGCG administrated for 7 days (30 mg/kg/d) 
reduced TF activity by 46.6±17% as compared to control animals (n=5; p<0.05; figure 
2D). In line with this observation, EGCG also impaired TNF-α induced TF expression 
in cultured HASMC and HUVEC (n=4; p<0.01; supplemental figure 2 and 3). 
Pretreatment of HAEC with the monoclonal 67LR blocking antibody MLuC5 blunted 
the inhibitory effect of EGCG on TF protein expression as compared to cells treated 
with the isotype control (n=4; *p<0.001 vs TNF-α alone; figure 2E). A similar effect 
was observed using a polyclonal 67LR antibody (n=4; *p<0.001; data not shown). 
LDH release was not altered by any of the EGCG concentrations used (n=4; p=NS; 
  
data not shown). 
 
67LR inhibits TF mRNA expression and promoter activity but not TNF-α 
induced NFkB activation  
TNF-α induced TF mRNA expression within 2 hours of stimulation as 
determined by real-time PCR analysis (n=5; *p<0.0001; Figure 3A). EGCG (30 µM) 
impaired TNF-α induced TF mRNA expression by 74% as compared to TNF-α alone 
(n=5; *p<0.001; Figure 3A). EGCG (30 µM) did not alter TNF-α stimulated IkB-α 
degradation nor TNF-α induced nuclear translocation and DNA binding activity of the 
NF kappa B subunit p65 (n=4; p=NS, figure 3B and 3C). To assess whether the 
effect on TF mRNA was mediated via promoter inhibition, the impact of EGCG on TF 
promoter activity was analyzed after adenoviral transduction of endothelial cells with 
firefly luciferase under control of the human minimal TF promoter (-221 bp to +121 
bp). TNF-α enhanced TF promoter activity by 2.2 fold as compared to control 
conditions (n=4; *p<0.001; Figure 3D); while EGCG (30 µM) inhibited this effect by 
51% (n=4; *p<0.001; Figure 3D). 
 
67LR inhibits JNK1/2 phosphorylation  
To determine whether 67LR inhibited MAP kinases, phosphorylation of these 
mediators was assessed at different time points after TNF-α stimulation. TNF-α (5 
ng/mL) transiently activated JNK1/2, ERK, and p38; maximal activation was 
observed after 15 minutes and returned to basal levels within 60 minutes (Figure 4A). 
EGCG inhibited phosphorylation of JNK by 46% as compared to TNF-α alone (n=4; 
*p<0.01; Figure 4B), while phosphorylation of ERK and p38 was not altered (n=4; 
p=NS; Figure 4B). Total expression of JNK 1/2, ERK, and p38 remained unaffected 
at all time points examined (Figure 4A). Targeting of JNK1 and JNK2 with specific 
  
siRNA impaired TNF-α induced TF expression by 33% and 60%, respectively as 
compared to TNF-α alone (n=4; p<0.05 for JNK1 vs TNF-α alone and p<0.01 for 
JNK2 vs TNF-α alone; figure 5A). Inhibition of JNK 1 and 2 phosphorylation with 
SP600125 mimicked  the effect of siRNA on TF protein expression (n=4; *p<0.001; 
Figure 5B) and abolished TNF-α induced TF promoter activation (n=4; *p<0.001; 
Figure 5C). The inhibitory effect of EGCG on JNK phosphorylation was prevented by 
pretreatment with the 67LR blocking antibody MLuC5 (n=3; p<0.01; Figure 5D). 
 
Neither 67LR nor JNK 1/2 regulate VCAM-1 expression 
Western blot analysis revealed that TNF-α induced VCAM-1 expression (n=4; 
p<0.001; Figure 5A) in HAEC. Neither 67LR activation by laminin or EGCG (1-30 µM) 
nor JNK inhibition by SP600125 (n=4; p=NS; Figure 6A, 6B, and 6C) impaired TNF-α 
induced VCAM-1 expression. Similar to the result obtained in HAEC with EGCG in 
HUVEC (n=4; p=NS; supplemental figure 4).  
 
  
  
Discussion 
 
This study demonstrates that activation of the 67LR by laminin or EGCG 
inhibits TNF-α induced TF expression in endothelial cells. Moreover, administration of 
EGCG in C57BL6 mice diminishes TF activity in carotid artery lysates. This effect is 
mediated at the transcriptional level via reduced phosphorylation of the JNK isoforms 
p46 and p54 (JNK1 and JNK2) and impaired TF promoter activation. In contrast, 
67LR does not affect the JNK 1/2 independent expression of VCAM-1 in these cells.  
Endothelial cells line the vascular lumen while their abluminal surface interacts 
with the basal membrane. The laminin 10 isoform is the main component of the basal 
membrane in mature vessels, separating endothelial cells from interstitial collagens 
[7]. It is notable that the laminin most widely used for in vitro studies was isolated 
from mouse Engelberth-Holm-Swarm tumors corresponding to the laminin 1 isotype 
[7]. This form of laminin, however, does not occur in the endothelial cell basement 
membrane and therefore might constitute a limitation for previous studies. Therefore, 
the effect of laminin on TNF-α induced TF expression was analysed in this study 
using commercially available human laminin and mainly containing the laminin 10 
isoform.  
Separation of endothelial cells from interstitial collagens plays an important 
role in maintaining vessel wall integrity, since laminin and interstitial collagen 
modulate endothelial function in a differential manner. Indeed, collagen activates 
endothelial Src kinase as well as the GTPase Rho while suppressing the activity of 
the GTPase Rac, leading to disruption of intercellular junctions, cell proliferation, tube 
formation, and initiation of angiogenesis [5,6]. In contrast, laminin antagonizes these 
effects [5,6]. In line with these findings, cells growing on laminin proliferate slower 
than those on fibronectin. The present study demonstrates that endothelial cells 
  
growing on laminin express lower levels of TF upon stimulation with TNF-α as 
compared to those on fibronectin. This observation is consistent with the 
interpretation that basal membrane associated laminin preserves vascular integrity 
by reducing endothelial cell activation.  
The interaction between 67LR and the laminin subunit β1 is an essential 
component of cellular adhesion to the basement membrane [8]. The polyphenol 
EGCG has been characterized as a ligand for 67LR. Experiments performed in 
human lung cancer cells demonstrate that EGCG mediated growth inhibition is 67LR 
dependent and that EGCG binds to the 67LR with a Kd value of 39.9 nM [10]. In 
endothelial cells, 67LR is involved in shear stress induced endothelial nitric oxide 
synthase activation, indicating that this receptor has functional properties beyond its 
known role in cell adherence [9]. The present study demonstrates that 67LR is 
abundantly expressed on the surface of human aortic endothelial cells and that 
activation of 67LR by laminin or EGCG inhibits TF protein expression and activity.  
TF expression is a major trigger of the thrombotic response, and high levels of 
TF contribute to thrombus formation following plaque rupture or erosion [4]. The 
proinflammatory cytokine TNF-α [22]  and histamine have been identified as potent 
inducers of TF expression [2]. Similar to laminin, EGCG inhibited TNF-α and 
histamine induced TF expression in a concentration dependent manner. The MAP-
kinases JNK1/2, p38, and ERK regulate TF expression at the transcriptional level in 
response to both agonists [23]. 67LR activation by EGCG resulted in decreased 
phosphorylation of the MAP kinase JNK1/2 and decreased expression of TF. 
Conversely, 67LR blockade abolished the inhibitory effects of EGCG on JNK1/2 
activation and TF expression. Finally, specific targeting of JNK1/2 with siRNA or the 
pharmacological inhibitor SP600125 reduced TNF-α induced TF promoter activity, 
RNA and protein expression. Hence, EGCG inhibits TF expression by decreasing 
  
JNK activation.  
An involvement of MAP kinases in laminin signalling has been described in 
tumor cells [24]. To confirm the role of JNK1/2 in mediating the effects of 67LR 
activation on endothelial TF, TNF-α induced VCAM-1 expression was analyzed, 
since this protein, is regulated independent of JNK1/2 in this cell type [25]. Neither 
laminin nor EGCG affected endothelial VCAM-1 expression, confirming that 67LR 
activation specifically inhibits JNK1/2. It is of note that some previous studies 
described a role for JNK1/2 in VCAM-1 induction in vascular cells [26;27]. However, it 
should be considered that different cell types, different experimental protocols, and 
different SP600125 concentrations may account for these discrepancies. TNF-α 
induced VCAM-1 expression depends on NFkB activation in endothelial cells [28]. 
EGCG did not affect IkB-α degradation nor NFkB activation after TNF-α stimulation in 
HAEC. This result strongly suggests that EGCG inhibits TF expression via a 
transcription factor other than NFkB and located downstream of JNK1/2, such as AP-
1, which is known to regulate TF promoter activation [29]. 
It is of clinical relevance that the inhibition of TF mRNA and protein expression 
reached a significant level when EGCG was applied at concentrations as low as 1 
and 3 µM. Such levels of EGCG have been measured in human plasma following the 
oral intake of green tea extract or purified EGCG [30,31]. Thus, the inhibitory effect of 
67LR activation by EGCG occurred at clinically relevant concentrations and might 
account at least in part for the cardioprotective effects of green tea consumption. 
In summary, this study demonstrates that 67LR activation by laminin or the 
polyphenol EGCG inhibits endothelial TF expression and activity. Hence, it describes 
a new mechanism by which the basement membrane modulates the hemostatic 
balance in intact vessels and identifies 67LR as a potential target for the 
development of novel anti-thrombotic therapies.  
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Figure Legends 
 
Figure 1: Laminin inhibits TF protein expression 
A. 67LR is abundantly expressed on the surface of HAEC. 20x magnification. B. 
TNF-α induced TF expression is inhibited when cells are grown on laminin as 
compared to fibronectin. *p<0.001. 
 
Figure 2: 67LR inhibits TF protein expression  
EGCG inhibits TNF-α (A) and histamine (B) induced TF protein expression in 
HAEC. *p<0.001 vs TNF-α and histamine alone. C. EGCG decreases TNF-α induced 
TF surface activity. *p<0.001 vs TNF-α alone. D. In C57BL6 mice EGCG reduces TF 
activity. *p<0.05 vs control. E. Treatment with a 67LR blocking antibody (MLUC5) 
abrogates the inhibitory effect of EGCG on TF expression. *p<0.01 vs TNF-α alone. 
All blots are normalized to GAPDH. 
 
Figure 3: 67LR inhibits TF promoter and TF mRNA expression 
A. Real-time PCR analysis demonstrates that EGCG impairs TF mRNA 
expression in HAEC. Values are normalized to L28 expression. *p<0.0001 vs TNF-α 
alone. B. Luciferase assay shows that EGCG inhibits TNF-α induced TF promoter 
activity. Values are normalized to total protein concentration. *p<0.001 vs TNF-α 
alone. 
 
Figure 4: EGCG impairs JNK1/2 phosphorylation 
A. TNF-α induces a transient phosphorylation of the MAP-kinases JNK, ERK, 
and p38. EGCG inhibits phosphorylation of JNK1/2, but not ERK and p38. No change 
in total expression of JNK, ERK, and p38 is observed. B. EGCG inhibits activation of 
  
JNK, but not ERK and p38. *p<0.01 vs TNF-α alone.  
 
Figure 5: 67LR activation mediates impairment of JNK1/2 activation by EGCG 
A. Transfection with siRNA against JNK1 and JNK2 mRNA inhibits TNF-α 
induced TF expression. *p<0.05 vs TNF-α alone. SP600125, a specific JNK inhibitor, 
impairs TF protein expression (B) and TF promoter activation (C). *p<0.001 vs TNF-α 
alone. D. Treatment with a 67LR blocking antibody blunts the inhibitory effect of 
EGCG on JNK activation. *p<0.001 vs TNF-α alone. 
 
Figure 6: Neither 67LR nor JNK regulate VCAM-1 expression 
A. Laminin does not alter TNF-α induced VCAM-1 expression in HAEC as 
compared to fibronection. p=NS. B. EGCG has no effect on TNF-α induced VCAM-1 
expression. p=NS vs TNF-α alone. C. JNK inhibition with SP600125 does not affect 
TNF-α induced VCAM-1 expression. p=NS vs TNF-α alone. All blots are normalized 
to GAPDH. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Supplemental figure 1. EGCG does not affect TFPI expression. 
Incubation with EGCG does not alter endothelial TFPI expression. p=NS vs 
unstimulated control and p=NS vs TNF-α alone. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Supplemental figure 2: EGCG inhibits TF expression in HASMC. 
ECGC inhibits TNF-α induced TF expression in HASMC. *p<0.01 vs TNF-α alone. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Supplemental figure 3: EGCG impairs TF expression in HUVEC. 
In HUVEC ECGC impairs TNF- α induced TF expression. *p<0.01 vs TNF-α alone. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Supplemental figure 4: EGCG does not alter VCAM-1 expression in HUVEC. 
EGCG has no effect on TNF-α induced VCAM-1 expression in HUVEC. p=NS vs 
TNF-α alone. 
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Abstract 
 
Aims. Berberine (BBR) is a novel natural hypolipidemic agent. This study 
investigates whether BBR, similar to statins, exerts pleiotropic effects on endothelial 
tissue factor (TF) expression.  
Methods and Results. BBR enhanced tumor necrosis factor-α (TNF-α) and 
thrombin induced TF expression in human endothelial cells by 3.5-fold. These effects 
were paralleled by an enhanced TF surface activity. In contrast, expression of TF 
pathway inhibitor was impaired. BBR enhanced TNF-α induced TF mRNA 
expression; however, TF promoter activity was inhibited. Activation ERK and p38 
remained unaffected, while c-Jun terminal NH2 kinase was inhibited. BBR reduced 
TF mRNA degradation rates, prolonging its half-life from 1.1 to 4.3 hours. The HMG-
CoA reductase inhibitor simvastatin impaired thrombin induced TF expression, and 
BBR blunted this inhibition. Simvastatin did not affect TNF-α induced TF expression, 
and BBR enhanced TF under these conditions. Administration of BBR (100 mg/kg/d) 
increased TF activity and impaired TFPI expression in carotid artery of ApoE-/- mice. 
Conclusions. BBR enhances TF via mRNA stabilization at clinically relevant 
concentrations. Clinical application of BBR, either as an alternative to or in 
combination with statins, should be considered with caution. 
 
Key Words: Berberine, Tissue Factor, Tissue Factor Pathway Inhibitor, mRNA 
Stability, Simvastatin 
 
 
 
Introduction 
 
Arterial thrombosis is the critical event in acute coronary syndromes, 
peripheral ischemia, and stroke. Tissue factor (TF) plays an essential role in 
coagulation by binding factor VII, which activates factor X, finally leading to thrombin 
generation [1]. TF expression is detected in a variety of cell types within the 
atherosclerotic vessel wall and is induced by inflammatory mediators such as TNF-α, 
histamine, or lipopolysaccharide [2,3,4,5]. Elevated levels of TF are indeed present in 
plaques from patients with unstable angina and enhance plaque thrombogenicity; 
further, an involvement of TF in drug-eluting stent thrombosis has been discussed as 
well [6,7,8]. Tissue factor pathway inhibitor (TFPI) acts as the direct endogenous 
inhibitor of the TF/FVIIa complex [9]. Increasing evidence indicates that modulation of 
the physiological balance between TF and TFPI has an important impact on 
thrombus formation [10,11]. 
Berberine (BBR), an alkaloid isolated from the Chinese herb huanglian (Coptis 
chinensis), has been extensively used in traditional Chinese medicine. Recently, 
BBR was identified as a promising lipid-lowering drug, potently upregulating hepatic 
low-density lipoprotein (LDL) receptor expression. This effect occurred via LDL 
receptor mRNA stabilization rather than increased promoter activity and required 
extracellular signal regulated kinase (ERK) activation [12]. Further studies revealed 
that the BBR induced LDL receptor mRNA stabilization involved novel regulatory 
proteins located downstream of the ERK pathway and able to interact with 
sequences in the proximal section of the LDL receptor mRNA 3’ untranslated region 
(UTR) [13]. 
Since these observations suggest a therapeutic application of BBR, either as a 
 
 
 
monotherapy or in combination with statins, this study adressed the question whether 
BBR, similar to statins, exerts pleiotropic effects on endothelial TF expression. 
 
 
 
Methods 
 
Cell Culture 
Human aortic endothelial cells (HAEC; Clonetics, Allschwil, Switzerland) were 
cultured as described [3,4]. Adhering cells were grown to confluence in 3 cm dishes 
and rendered quiescent in medium supplemented with 0,5% fetal bovine serum for 24 
hours before stimulation with 5 ng/mL TNF-α (R&D Systems, Minneapolis, MN) or 1 
U/ml thrombin (Sigma, St. Louis, MO). Cells were treated with BBR (Cayman 
Chemical, Ann Arbor, MI), simvastatin (Sigma), or both for 60 min prior to stimulation. 
Cytotoxicity was assessed with a colorimetric assay for detection of lactate 
dehydrogenase release (Roche, Basel, Switzerland). 
 
Western Blot 
Protein expression was determined by Western blot analysis as described 
[3,4]. Antibodies against human TF and TFPI (both from American Diagnostica, 
Stamford, CT) were used at 1:2000 dilution. Antibodies against  phosphorylated p38 
MAP kinase (p38), p44/42 MAP kinase (extracellular signal regulated kinase [ERK]), 
and c-Jun NH2-terminal kinase (JNK; all from Cell Signaling, Danvers, MA) were 
used at 1:1000, 1:5000, and 1:1000 dilution, respectively. Antibodies against total 
p38, ERK, and JNK (all from Cell Signaling) were used at 1:2000, 1:5000, and 
1:1000 dilution, respectively. All blots were normalized to glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) expression (1:5000 dilution, Chemicon 
International, Temecula, CA).  
 
TF Surface Activity 
TF activity at the surface of HAEC was analyzed using a colorimetric assay 
 
 
 
(American Diagnostica) [3,4]. TF/FVIIa complex converted human factor X to factor 
Xa, which was measured by its ability to metabolize a chromogenic substrate. TF 
activity was measured against a standard curve performed with lipidated human TF 
to assure that measurements were taken in the linear range of detection. 
 
Real Time PCR 
Total RNA was extracted from HAEC using TRIzol Reagent (Invitrogen, 
Carlsbad, CA). Conversion of total cellular RNA to cDNA was carried out with 
Moloney murine leukemia virus reverse transcriptase and random hexamer primers 
(Amersham Biosciences, Piscataway, NJ) in a final volume of 33 µl using 4 µg of 
cDNA. Real time PCR was performed in an MX3000P PCR cycler (Stratagene, 
Amsterdam, The Netherlands) as described [7,8]. All experiments were performed 
using the SYBR Green JumpStart kit (Sigma). Each reaction (25 µl) contained 2 µl 
cDNA, 1 pmol of each primer, 0.25 µl of internal reference dye, and 12.5 µl of 
JumpStart Taq ReadyMix (containing buffer, dNTPs, stabilizers, SYBR Green, Taq 
polymerase and JumpStart Taq antibody). The following primers were used: for full 
length human TF (F3): sense 5’-TCCCCA-GAGTTCACACCTTACC–3’, antisense 5’–
CCTTTCTCCTGGCCCATACAC–3’ (bases 843-863 of F3 cDNA; NCBI no. NM 
001993); for human ribosomal L28: sense 5’-GCATCTGCAATGGATGGT-3’, 
antisense 5’–CCTTTCTCCTGGCCCATACAC-3’. The amplification program 
consisted of 1 cycle at 95˚C for 10 min, followed by 35 cycles with a denaturing 
phase at 95˚C for 30 s, an annealing phase at 60˚C for 1 min, and an elongation 
phase at 72˚C for 1 min. A melting curve analysis was performed after amplification 
to verify the accuracy of the amplicon, and PCR products were analyzed on an 
ethidium bromide stained 1% agarose gel. In each real-time PCR run for TF and L28, 
 
 
 
a calibration curve was included that was generated from serial dilutions of purified 
amplicons.  
 
TF Promoter Activity 
The TF promoter (-227 bp to +121 bp) was inserted upstream of the luciferase 
cDNA and the SV40 PolyA signal into the multiple cloning site of the helper vector 
VQAd5K-NpA (provided by ViraQuest Inc., North Liberty, IA). In a first step, HindIII 
and BamHI restriction sites of VQAd5K-NpA were used to insert a 2.7 kb 
HindIII/BamHI restriction fragment of pGL2-Basic vector (Promega, Madison, WI) 
containing the luciferase cDNA and the SV40 PolyA signal. In a second step, a 0.3 
kb Kpnl restriction fragment from a human TF promoter plasmid including the TF 
minimal promoter [14] kindly provided by Dr. Nigel Mackman (University of North 
Carolina, Chapell Hill; NC) was ligated into the Kpnl site of the resulting construct. 
The whole insert was sequenced to confirm its orientation and the absence of any 
nucleotide substitutions. This construct named VQAd5/hTF/Luc was used for 
production of an adenoviral vector (Ad5/hTF/Luc). For transduction, the vector was 
added to HAEC at an moi of 60 pfu/cell for 1 hour and then removed. HAEC were 
kept in growth medium for 24 hours and then serum-starved for 24 hours prior to 
TNF-α stimulation with or without BBR (30 µmol/L) for 5 hours. Firefly luciferase 
activity was determined in cell lysates using a luminometer (Berthold Technologies, 
Bad Wildbad, Germany). Protein concentration of the cell lysates was determined for 
normalization of luciferase activity. 
 
TF mRNA Stability 
2 hours after TNF-α stimulation, transcription was stopped by addition of 
actinomycin D (Sigma, St. Louis, MO) at a concentration of 10 µg/ml. At the indicated 
 
 
 
time points following addition of actinomycin D, cells were washed with PBS and 
immediately lysed with TRIzol reagent for RNA isolation. RNA was processed for 
real-time PCR analysis as described above. Values were then plotted on a 
logarithmic scale as a function of time, and the half-life was calculated using linear 
equation [15]. 
 
In vitro RNA decay assay 
A 297-bp PCR fragment from 3‘-UTR of the human TF cDNA was subcloned into the 
BamHI and XhoI restriction sites of pBluescript II KS (+) (Stratagene). This construct 
was linearized with KpnI and used as a template for generation of a 390-nt riboprobe 
labeled with 50 µCi [α-32P]UTP (25 Ci/mmol, Perkin Elmer) using T7 RNA 
polymerase (Promega) and m7G5’pppG (cap). The labeling reaction was performed 
for 1 h at 30°C followed by removal of the DNA template through incubation with RQ1 
RNase-Free DNase for 15 min at 37°C. The riboprobe was then purified on 6% Tris 
boric acid-EDTA buffer-urea polyacrylamide gel. Cytoplasmic proteins were extracted 
in lysis buffer (25 mM HEPES, pH 7.6, 5 mM MgCl2, 1.5 mM KCl, 2 mM DTT, 1 mM 
PMSF, 0.1% NP-40). 32P-labeled riboprobe (105 cpm) was added to 20 µg 
cytoplasmic protein extracts (1 µg protein/µl) in buffer (20 mM HEPES (pH 7.0), 20% 
glycerol, 100 mM KCl, 0.2 mM EDTA, 1 mM DTT, 1mM PMSF), and this mixture 
incubated at room temperature in RNA-binding buffer (20 µl) containing 20 mM 
HEPES (pH 7.0), 20% glycerol, 100 mM KCl, 3 mM MgCl2, 2 mM DTT, 0.5 % NP-40, 
yeast RNA (1 µg), and heparin (1 µg). Aliquots were removed at 0 min, 15 min, 30 
min, and 60 min time-points and placed in 100 µl stop solution containing 25 mM Tris 
(pH 7.6), 400 mM NaCl, 0.1 % SDS, and yeast RNA (10 µg). Samples were extracted 
with phenol-cloroform, precipitated with ethanol, and separated by gel-
 
 
 
electrophoresis on 5% polyacrylamide gel containing 7M urea. Bands were visualized 
by autoradiography using a phosphoimager. 
 
In vivo study 
For analysis of TF and TFPI in vivo, 10 week old male ApoE-/- mice (C57BL6, 
Jackson Laboratories, Bar Harbor, ME) weighing an average of 28g were fed a 
normal chow diet (KLIBA NAFAG, Kaiseraugst, Switzerland) and treated with BBR at 
a dose of 100 mg/kg/d orally for 10 days. Control ApoE-/- mice matched for age, sex, 
and weight received an equal volume of vehicle (0.9% saline). Mice were then 
euthanized and the left common carotid artery harvested for analysis of TF activity 
and TFPI expression. Analysis of TF activity in the arterial homogenates was 
performed using a colorimetric assay (American Diagnostica). TFPI expression was 
assessed by ELISA (American Diagnostica). 
 
Statistics 
Data are presented as mean±SEM. Statistical analysis was performed by 
ANOVA or 2-tailed unpaired Student t-test as appropriate. A value of p<0.05 was 
considered significant. All results are representative of at least 4 independent 
experiments. 
 
 
 
 
Results 
 
Berberine enhances TF protein expression and surface activity 
HAEC were stimulated with TNF-α (5 ng/ml) or thrombin (1 U/ml) for 5 hours. 
1 hour pretreatment with BBR (1-30 µmol/l) enhanced TNF-α induced TF expression 
in a concentration-dependent manner with an EC50 value of 2 µmol/l (n=5; p<0.01; 
Figure 1A); the maximal effect occurred at 30 µmol/l and resulted in a 3.4-fold higher 
expression as compared to TNF-α alone. Similarly, BBR enhanced thrombin induced 
TF expression by 3.3-fold as compared to thrombin alone (n=5; p<0.05; Figure 1B). 
BBR did not alter TF expression under basal conditions (n=10; p=NS; Figure 1A and 
B). The effect of BBR on TF expression was paralleled by an enhanced TF surface 
activity, which was 1.6 times higher than that by TNF-α alone (n=4; p<0.0005; Figure 
1C). BBR did not alter TF surface activity under basal conditions (n=4; p=NS; Figure 
1C).  
BBR (1-30 µmol/l) inhibited TFPI expression of TNF-α stimulated HAEC by 
45±15% as compared to TNF-α alone with an EC50 value of 5.7 µmol/l (n=4; p<0.05; 
Figure 1D). Similarly, BBR impaired basal TFPI expression by 52±12% (n=4; 
p<0.005; Figure 1D). 
LDH release was not affected by any BBR concentration used (n=4; p=NS; 
data not shown) indicating that BBR did not exert cytotoxic effects.  
 
Berberine enhances TF mRNA level  
Real-time PCR revealed that TNF-α induced TF mRNA expression within 2 
hours of stimulation (n=5; p<0.0001; Figure 2A). BBR (30 µmol/l) enhanced TNF-α 
induced TF mRNA expression by 1.6-fold as compared to TNF-α alone (n=5; p<0.05; 
 
 
 
Figure 2A).  
 
Berberine inhibits TF promoter activity  
To assess whether the effect on TF mRNA was mediated by enhanced 
transcription, the impact of BBR on TF promoter activity was analyzed after 
transfection of HAEC with a plasmid expressing firefly luciferase under control of the 
human TF promoter (-221bp to +121bp). TNF-α enhanced TF promoter activity by 
2.9-fold as compared to control conditions (n=4; p<0.0001; Figure 2B). Treatment 
with BBR (30 µmol/l) impaired promoter activation (n=4; p<0.001; Figure 2B). BBR 
did not affect basal promoter activity (n=4; p=NS; Figure 2B). 
 
Berberine inhibits JNK phosphorylation 
To determine whether inhibition of TF promoter activity was paralleled by 
inhibition of MAP kinases, phosphorylation of these mediators was assessed at 
different time points after TNF-α stimulation. TNF-α (5 ng/mL) transiently activated 
JNK, ERK, and p38; maximal activation was observed after 15 minutes and returned 
to basal levels within 60 minutes (Figure 3A). Treatment with BBR inhibited 
phosphorylation of JNK by 48±12% as compared to TNF-α alone (n=4; p<0.05; 
Figure 3B), while phosphorylation of ERK and p38 was not significantly reduced 
(n=4; p=NS; Figure 3B). Total expression of JNK, ERK, and p38 remained unaffected 
at all time points examined (Figure 3A). 
 
Berberine stabilizes TF mRNA  
TF mRNA was quantified by real-time PCR at different time points after 
addition of the inhibitor of transcription, actinomycin D. BBR (30 µmol/L) delayed TF 
mRNA degradation, increasing the half-life of TF mRNA from 64 min under control 
 
 
 
conditions to 260 min in the presence of BBR (n=5; Figure 4A). To study the role of 
the 3'-untranslated region (3’-UTR), which includes five AU-rich elements known to 
mediate TF mRNA stability, an in vitro RNA decay assay was performed. A 32P-
radiolabeled 390 nt transcript containing the last 297 nt of the TF 3’-UTR was 
incubated with cytoplasmatic extracts generated from endothelial cells either 
untreated or treated with TNF-α, berberine, or TNF-α+berberine. Analysis of 
transcript decay by densitometry showed no significant difference in transcript 
degradation rate between the different groups (n=4; p=NS; Figure 4B). 
 
Berberine abrogates the inhibitory action of statins on TF expression  
Statins exert pleiotropic anti-thrombotic effects through inhibition of TF 
expression in different cell types including endothelial cells [16,17,18].  Since statins 
and BBR exhibit additive lipid-lowering effects, the impact of such a combination on 
endothelial TF protein expression was examined. Simvastatin (1 µmol/l) inhibited 
thrombin induced TF expression by 40±14% as compared to thrombin alone (n=5; 
p<0.05; Figure 5A), while such an effect was not observed in TNF-α stimulated 
endothelial cells (n=4; p=NS for TNF-α + simvastatin vs TNF-α alone; Figure 5B). 
BBR antagonized the inhibitory effect of simvastatin on thrombin induced TF 
expression (n=5; p<0.05 for simvastatin + BBR vs simvastatin alone; p=NS for 
simvastatin + BBR vs BBR alone; Figure 5A). In both thrombin and TNF-α stimulated 
HAEC, treatment with simvastatin had no effect on the enhanced TF expression 
occurring in the presence of BBR (n=4; p=NS; Figure 5B).  
 
BBR enhances TF and inhibits TFPI in vivo 
The effect of berberine on expression of TF and TFPI was assessed in ApoE-/- 
mice. Animals were treated for 10 days with berberine (100 mg/kg/d). The left 
 
 
 
common carotid artery was harvested for analysis of TF activity and TFPI expression. 
TF activity was enhanced by nearly 2-fold in the berberine treated group (n=7; 
p<0.05; Figure 6A). This increase in TF activity was paralleled by a 43.5% decrease 
in TFPI expression as compared to control (n=7; p<0.05; Figure 6B). 
 
  
 
 
 
Discussion 
 
This study demonstrates that BBR, at clinically relevant concentrations 
stimulating hepatic LDL receptor expression [12], enhances TNF-α and thrombin 
induced endothelial TF expression via stabilization of TF mRNA. Moreover, BBR 
inhibits endothelial TFPI expression, and abrogates the inhibitory effects of statins on 
endothelial TF. Similar effects on TF and TFPI are observed in ApoE-/- mice treated 
with BBR. These observations suggest that application of BBR as a lipid-lowering 
medication, either alone or in combination with a statin, may favor the development 
of thrombosis, in particular in the inflammatory environment of atherosclerotic lesions 
[19]. 
As endothelial cells are situated at the luminal surface of vessels and thereby 
exposed to circulating FVII, modulation of TF expression at the endothelial surface 
can have major consequences for thrombus formation. BBR enhanced TNF-α and 
thrombin induced TF expression, suggesting that it promotes thrombus formation 
under both inflammatory and prothrombotic conditions. Since TF is inhibited by TFPI, 
the balance of these factors is essential for vascular homeostasis [9,10,20]. In 
addition to enhancing TF, BBR impaired basal as well as TNF-α induced endothelial 
TFPI expression, which represents an additional prothrombotic potential. These 
effects of BBR on TF and TFPI may be particularly relevant in acute coronary 
syndromes, which are usually triggered by vascular inflammation leading to thrombus 
formation. 
The BBR concentrations applied in vitro (1 to 30 µmol/l) are comparable to 
those used in another study [12], where concentrations ranged from 0.5 to 15 µg/ml 
corresponding to 1.3 to 40 µmol/l. The pharmacokinetics of berberine in humans are 
 
 
 
barely understood and still need to be characterized. However, a study performed in 
patients with congestive heart failure reported that oral administration of 1.2 g BBR 
per day led to plasma concentrations of 190±0.08 ng/ml (0.5±0.03 µmol/l) [21]. For 
the in vivo animal studies performed by others as well as for our own in vivo 
experiments, BBR was administrated orally at a dose of 50 and 100 mg/kg/d 
corresponding to an oral intake of 3 and 6 g BBR per day, respectively, for an adult 
weighing 60 kg [12]; hence, BBR intake was higher than in the study performed in 
humans, suggesting that BBR plasma concentrations may well reach values of 2 
µmol/l under these conditions. The berberine mediated effects on endothelial TF 
were statistically significant at concentrations as low as 1 µmol/l, and consistent with 
a biologically relevant concentration range, the in vivo effects of BBR on TF and TFPI 
were similar to those observed in human cells. 
The MAP kinases JNK, ERK, and p38 are critically involved in mediating 
transcriptional regulation of TF expression in response to both TNF-α and thrombin 
[1]. Although BBR enhanced TF mRNA levels, it inhibited activation of JNK without 
affecting that of ERK and p38, and, in line with this observation, impaired TF 
promoter activation. These data indicate that BBR upregulates TF mRNA by a post-
transcriptional mechanism able to counteract the impaired TF promoter activation. 
Analysis of TF mRNA decay rates indeed confirmed that BBR prolonged the half life 
of TF mRNA from 64 to 260 minutes, highlighting the crucial role of mRNA stability in 
the regulation of TF expression. A similar effect on the half life of TF mRNA was 
observed with dexamethasone in human monocytes [5,22]. The importance of mRNA 
stability in mediating TF expression, however, varies depending on the stimulus 
involved; indeed, LPS induces TF mainly by enhancing mRNA stability rather than 
increasing the rate of transcription, while the opposite effect accounts for the action 
of PMA [23]. Hence, it is conceivable that the mechanism of action of BBR on 
 
 
 
endothelial TF expression differs depending on the stimulus activating the 
endothelium. 
In mammalian cells, AU sequences regrouped to AUUUA pentamers in so-
called AU-rich elements (ARE) located in the 3’ untranslated region of mRNA are 
known to modulate mRNA decay [12,24,25]. ARE have been described in the 3’-UTR 
of human TF mRNA and are involved in TF mRNA turnover [22,26]. Analysis of the 
decay rates of a 390 nt transcript containing the last 297 nt of the TF 3’-UTR 
suggested that the stabilizing effect of berberine on TF mRNA is not mediated by 
elements within the last 297 nt of the TF 3’-UTR since there was no difference in 
degradation rates of the transcript in the presence of cytoplasmatic extracts from 
cells treated with or without BBR. 3’-UTR ARE and their binding proteins are not the 
only regulators of mRNA stability; other mechanisms such as inhibition of 
translational elongation or the presence of stabilizing sequences located in the 5’-
UTR can modulate mRNA decay as well [23,24]. So far, however, it remains 
unknown whether the latter mechanisms are involved in regulating TF mRNA 
stability. 
Statins are among the most-widely prescribed drugs, and the indications for 
their prescription have been extended over the years. Besides their well established 
lipid-lowering properties, statins exert cardio-protective pleiotropic effects [27,28]. 
Simvastatin indeed inhibited thrombin induced endothelial TF expression; however, 
TNF-α induced TF expression was not affected, indicating that such pleiotropic 
effects are modulated by the mediators involved in endothelial activation. Since 
another statin, cerivastatin, prevented TNF-α induced TF expression in human 
endothelial cells [29], this class of drugs may be heterogenous with regard to 
modulation of TF expression; alternatively, it should be considered that this 
experiment was performed in human umbilical vein endothelial cells and that 
 
 
 
experimental conditions might vary. BBR blunted the inhibitory effect of simvastatin 
on thrombin induced TF expression; moreover, it enhanced TF expression in cells 
treated with either TNF-α alone or TNF-α together with simvastatin. Both effects can 
be explained by the posttranscriptional mechanisms through which BBR enhances 
TF expression. 
 In summary, this study reveals that the natural lipid-lowering drug, BBR, 
enhances TF expression and in parallel decreases TFPI expression both in human 
endothelial cells and in arteries of ApoE-/- mice. Hence, BBR may favor the 
development of thrombus formation, particularly in patients with atherosclerotic 
lesions and those with acute coronary syndromes, since prothrombotic and 
inflammatory environments are often encountered under these conditions. Therefore, 
clinical application of BBR should be considered with caution, at least until large-
scale clinical trials have proven its safety. 
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Figure Legends 
 
Figure 1: BBR enhances TF protein expression and surface activity, and 
inhibits TFPI expression  
Western blot analysis demonstrates that BBR enhances TNF-α (A) and 
thrombin (B) induced TF protein expression. *p<0.01 vs TNF-α alone, *p<0.05 vs 
thrombin alone. C. BBR enhances TNF-α induced TF surface activity. *p<0.001 vs 
TNF-α alone. D. BBR inhibits TFPI protein expression. *p<0.005 vs control; **p<0.05 
vs. TNF-α alone. All blots are normalized to GAPDH  expression. 
 
Figure 2: BBR enhances TF mRNA expression, but inhibits TF promoter  
activation. 
A. Real-time PCR demonstrates that BBR enhances TNF-α induced TF 
mRNA expression. Values are normalized to L28 expression. *p<0.005 vs TNF-α 
alone. B. BBR inhibits TNF-α induced TF promoter activation. Values are normalized 
to total protein concentration. *p<0.001 vs TNF-α alone.  
 
Figure 3: BBR inhibits JNK phosphorylation. 
A. TNF-α leads to transient phosphorylation (Pho) of JNK, ERK, and p38. BBR 
inhibits activation of JNK, but not ERK and p38. Total (tot) expression of JNK, ERK, 
and p38 remains unchanged. B. BBR inhibits phosphorylation of JNK after 15 
minutes of TNF-α stimulation. *p<0.05 vs TNF-α alone. 
 
Figure 4: BBR stabilizes TF mRNA 
A. The decay of TF mRNA after addition of actinomycin D is monitored by real 
 
 
 
time PCR and normalized to L28 mRNA. Normalized TF mRNA levels are plotted in a 
semi-logarithmic scale as percentage of mRNA remaining versus time. The half-lives 
of TF mRNA are indicated. B. In vitro RNA decay assay reveals that the 3’UTR is not 
involved in the effect of BBR on TF mRNA. p=NS vs control. 
 
Figure 5: BBR abrogates TF inhibition by simvastatin 
A. Simvastatin inhibits thrombin induced TF expression as determined by 
western blot.**p<0.05 vs thrombin alone. BBR abrogates this effect. *p<0.05 vs 
thrombin alone, *p<0.05 vs thrombin + simvastatin. B. Simvastatin does not affect 
TNF-α induced TF expression. p=NS vs TNF-α alone. BBR enhances TF expression 
in the presence of simvastatin. *p<0.05 vs TNF-α alone, *p<0.05 vs TNF-α + 
simvastatin. 
 
Figure 6: BBR enhances TF and inhibits TFPI in vivo 
A. BBR enhances TF activity in ApoE-/- mice. *p<0.05 vs control. B. BBR 
inhibits TFPI expression in ApoE-/- mice. *p<0.05 vs control. 
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Abstract 
 
Objectives. To evaluate the impact of p110α inhibition on vascular smooth muscle 
(VSMC) and endothelial cell (EC) activation. 
Background. Impaired reendothelialization and stent thrombosis remain safety 
concerns associated with the use of drug-eluting stents DES, despite a reduction in 
restenosis rates. Phosphoinositide 3-kinase p110α (PI3K/p110α) controls crucial 
cellular processes including proliferation and chemotaxis, thereby representing an 
emerging drug target. However, its effect on vascular smooth muscle (VSMC) and 
endothelial cell (EC) activation remains unknown. 
Methods. PI3K/p110α was inhibited by treatment with the small molecule inhibitor   
PIK 75 or, alternatively, a specific siRNA. Proliferation and migration of VSMC and 
EC were assessed by cell number and Boyden chamber, respectively. Endothelial 
senescence and dysfunction were evaluated by β-galactosidase assay, Western 
blots for expression of eNOS, TF, and PAI-1, and organ chambers for isometric 
tension recording.  
Results. Inhibition of PI3K/p110α with PIK 75 or a specific siRNA selectively 
impaired proliferation and migration of VSMC while sparing EC completely. 
Treatment with PIK75 did not induce endothelial senescence nor inhibit eNOS 
expression or endothelium-dependent vascular relaxation. However, PIK 75 inhibited 
both basal and TNF-α induced expression of TF and PAI-1. In contrast to PIK 75, 
both rapamycin and paclitaxel inhibited endothelial proliferation and migration; 
moreover they induced expression of TF and PAI-1.  
Conclusions. Inhibition of PI3K/p110α impairs proliferation and migration of VSMC, 
but not EC. In addition to its potent antiproliferative and antimigratory effects on 
 
 
 
VSMC, targeting p110α inhibits the expression of prothrombotic mediators on EC. 
Hence, PI3K/p110α inhibition may offer new options in DES design. 
 
  
 
 
 
Introduction 
 
Revascularization by percutaneous transluminal coronary angioplasty (PTCA) 
and subsequent deployment of balloon-expendable stents has become the treatment 
of choice in symptomatic coronary artery disease. Because of procedure-related 
vascular injury and remodeling associated with high restenosis rates, stents designed 
to release anti-proliferative pharmacological agents have been developed. The 
introduction of rapamycin- and paclitaxel-eluting stents has resulted in a significant 
reduction of restenosis and target-vessel revascularization rates (TLR) when 
compared with bare-metal stents (BMS) (1-4). Despite this success, drug-eluting 
stents (DES) have failed to improve mortality when compared to BMS and recent 
trials have raised concerns over increased stent thrombosis rates associated with the 
use of DES (5-7). Indeed, impaired reendothelialization as well as prothrombotic 
effects of the eluted drug seem to play important roles in the pathogenesis of stent 
thrombosis observed with DES (8). Therefore the ideal DES should exert selective 
anti-proliferative effects on vascular smooth muscle cells, while being inert toward 
endothelial cell proliferation (9). 
By catalyzing the synthesis of phosphatidynol second messengers (PIP, PIP2, 
and PIP3), the phosphatidylinositol-3 kinase (PI3K) signaling pathway controls 
fundamental cellular processes such as cell survival, proliferation and differentiation 
(10). The class I PI3Ks consist of a dimer of a regulatory (p85α) and a catalytic 
subunit (p110α, p110β, and p110δ). Class I PI3ks are activated by tyrosine kinases 
or G- protein coupled receptors to catalyze the generation of PIP3, which modulates 
downstream targets such as the Rho GTPases or the Akt/PDK1 pathway (10). The 
implication of the PI3Ks in pathophysiological processes such as cancer 
 
 
 
development, inflammation, or thrombosis has made these enzymes an attractive 
therapeutic target and recent efforts have been taken to synthesize cell-permeable 
small molecule PI3K inhibitors such as the p110α inhibitor PIK 75 (11,12). However, 
because of their ubiquitous distribution, the understanding of how the several PI3K 
isoforms control normal physiological processes remains an important issue in the 
development of PI3K-targeting drugs. 
In the vasculature, p110α is the predominant isoform expressed in endothelial 
(EC) and vascular smooth muscle cells (VSMC). This study was designed to address 
the role of p110α in EC and VSMC proliferation and migration, which are critically 
involved in vascular remodelling following coronary intervention.  
 
 
 
  
 
 
 
Methods 
 
Cell culture 
Human aortic endothelial (HAEC), aortic smooth muscle (AoSMC) and human 
umbilical vein endothelial cells (HUVEC; all from Lonza, Basel, Switzerland) were 
cultured as described (13,14).  Saphenous vein smooth muscle cells (SVSMC) were 
isolated from human saphenous veins, characterized, and cultured as described (15). 
Briefly, AoSMC and SVSMC were grown on flasks (BD Biosciences, Bedford, MA, 
USA) in Dulbecco´s modified Eagle´s medium (DMEM) (Invitrogen, Basel, 
Switzerland) plus 10% fetal calf serum (FCS) using passages 5 to 9. HAEC and 
HUVEC were grown on fibronectin-coated flasks in endothelial cell growth medium-2 
(EGM-2) (Lonza) containing 10% FCS.  
 
Proliferation assay 
For cell counts AoSMC and SVSMC were seeded at a density of 15 000 cells 
per 35 mm dish and cultured in DMEM plus 10% FCS for 1 day. After 48 hours of 
serum withdrawal (DMEM plus 0.2% bovine serum albumin) the cells were incubated 
with either the small molecule p110α-inhibitor PIK 75 (Axon Biochemicals; 
Groningen, The Netherlands), paclitaxel, rapamycin, or the vehicle (0.1 % 
dimethylsulfoxide) (all from Sigma Aldrich, St. Louis, MO, USA) in the presence of 
platelet derived growth factor-BB (PDGF-BB, 10 ng/ml) and the cells trypsinized and 
counted 72 hours later.  
HAEC and HUVEC were seeded at a density of 20 000 cells per 35 mm dish 
and grown in EGM-2 plus 10% FCS for 24 hours. After rendering the cells quiescent 
 
 
 
in endothelial basal medium-2 (EBM-2) plus 0.1% FCS for 24 hours, the drug and 
EGM-2 plus 10% FCS were added and the cell number was assessed 72 hours later. 
Cell viability was assessed using a colorimetric assay for detection of lactate 
dehydrogenase release (Roche, Basel, Switzerland). 
 
Migration assay 
To assess migration in a 48-well modified Boyden chamber (Neuroprobe, 
Gaithersburg, MD, USA), AoSMC and SVSMC were seeded at a density of 70-80%, 
and kept in DMEM (containing 1g/l glucose) plus 10% FCS for 36-48h prior to the 
assay. Cells were trypsinized, washed with PBS and resuspended in control medium 
(DMEM plus 0.1% BSA) at a concentration of 500000 cells/ml. For drug 
pretreatment, cell suspensions were incubated with the corresponding drug for 1h at 
37°C. 50µl of cell suspension was loaded into the upper chamber which was 
separated by a collagen-coated polycarbonate membrane (Neuro Probe, Inc. PFB8; 
8µm pores) from the lower chamber containing DMEM (supplemented with 0.1% 
BSA) plus the chemoattractant PDGF-BB (10 ng/ml). DMEM with PDGF-BB 10 
ng/mL without the drug served as positive control, whereas DMEM alone was used 
as a negative control. Cells were allowed to migrate for 5 hours. Non-migrated cells 
were removed from the upper surface of the membrane with a cellscraper, and 
migrated cells on the bottom surface were fixed in ice-cold methanol for 10minutes 
followed by staining with Diff-Quik (Medion Diagnostics, Dudingen, Switzerland).  
For migration assays HAEC und HUVEC were processed the same way as 
AoSMC and SVSMC; except that they were seeded and kept in EGM-2 plus 10% 
FCS and resuspended in EBM-2 plus 0.2% FCS as control medium. For all EC’s a 
5µm pore size collagen-coated polycarbonate membrane was used. EGM-2 plus 
10% FCS alone represented the positive control, whereas EBM-2 supplemented only 
 
 
 
with 0.1% BSA was used as negative control. Migration for both vascular and 
endothelial cells was assessed after 5 hours by counting cells in 4 random fields at 
200x magnification using an Olympus BX51 microscope (Olympus Europa GmbH; 
Hamburg, Germany). 
 
siRNA knockdown experiments 
HAEC or AoSMC were plated on 6-well dishes 24 hours before transfection at a 
density of 20 000 and 15 000 cells respectively per well. Four siRNA oligonucleotide 
sequences (Microsynth, Balgach, Switzerland) reported to target the human p110α 
catalytic subunit, were used at a concentration of 25 nM and in combination: 
1015931 (sense sequence: 5’-GCUAUCAUCUGAACAAUUAUU-3’), 1015933 (sense 
sequence: 5’-GGAUAGAGGCCAAAUAAUAUU-3’), 1015935 (sense sequence: 5’-
GGACAACUGUUUCAUAUAGUU-3’), and 1015937 (sense sequence: 5’-
GCCAGUACCUCAUGGAUUAUU-3’). Scrambled siRNA (Microsynth; 1050124; 5’-
GAUCAUACGUGCGAUCAGATT-3’) was used as control. Transfection was 
performed using the lipofectamine RNAi Max system (Sigma Aldrich). After 
transfection, HAEC and AoSMC were transferred to their corresponding growth 
medium and trypsinized for counting after 72 hours. Knockdown of p110α was 
confirmed at the protein level by Western blot analysis. Immunoblotting was 
performed using a human anti-p110α antibody at a dilution of 1:5000 (Cell Signaling 
Technology, Danvers, MA, USA).  
 
Senescence associated β-galactosidase (SA-β-gal) assay 
HAEC were plated on fibronectin coated 6-well dishes and grown for 24 hours 
to 80% confluence in EGM-2 plus 10% FCS. After replacing the medium (EGM-2 
plus 10% FCS), cells were treated with vehicle (0.1% dimethylsulfoxide), PIK 75 (10 
 
 
 
nM), rapamycin (10 nM), or paclitaxel (10 nM) for another 24 hours. HAEC were 
washed 3 times with phosphate buffered saline (PBS) and fixed with 3% 
paraformaldehyde for 3 minutes. HAEC were incubated with a SA-β-gal stain solution 
for 14 hours and the proportion of SA-β-gal positive cells determined as previously 
described. 
 
Analysis of endothelial nitric oxide synthase (eNOS), tissue factor (TF), and 
plasminogen activator inhibitor-type I (PAI-1) expression 
HAEC were plated on 6-well dishes as previously described (13). For analysis 
of eNOS expression, HAEC were serum starved with EBM-2 plus 0.5% FCS for 24 
hours in the presence of PIK 75 (10 nM), rapamycin (10 nM), paclitaxel (10 nM), or 
the vehicle. For TF and PAI-1 expression analysis, subconfluent HAEC were 
rendered quiescent for 24 hours and treated with PIK 75 (10 nM), rapamycin (10 nM), 
paclitaxel (10 nM), or the vehicle for 1 hour prior to stimulation with TNF-α (5 ng/ml; 
R&D Systems, Minneapolis, MN, USA) for 5 hours. Protein expression was 
determined by Western blot analysis as described. Cells were lysed in 50 mmol/L Tris 
buffer, and 35 µg samples were loaded and separated by 10% sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis. Proteins were transferred to a 
polyvinylidene difluoride membrane by semidry transfer. Antibody to eNOS (BD 
Biosciences), TF (American Diagnostica), and PAI-1 (Santa Cruz Biotechnology Inc., 
Santa Cruz, CA, USA) were used at 1:2000, 1:2000 and 1:5000 dilution, respectively. 
All blots were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
expression (1:5000 dilution, Chemicon International, Temecula, CA, USA). The 
quantification of protein was performed by densitometric analysis using Scion Image 
Software (Scion Corp., Frederick, MD, USA) 
 
 
 
 
Statistical analysis 
Data are presented as mean ± SEM. Statistical analysis was performed by 
ANOVA. A value of p<0.05 was considered significant. All results are representative 
of at least 4 independent experiments.  
 
 
  
 
 
 
Results 
 
Pharmacological inhibition of p110α with PIK 75 inhibits vascular smooth 
muscle cell but not endothelial cell proliferation. 
Incubation of AoSMC and SVSMC with PIK 75 (0.1-10 nM) inhibited PDGF-BB 
induced proliferation of AoSMC and SVSMC after 72 hours in a concentration 
dependent manner (n=4; p<0.05; figure 1A). In contrast, PIK 75 did not exert any 
anti-proliferative effect on HAEC and HUVEC (n=4; p=NS; figure 1B). No cytotoxic 
effect of PIK 75 was observed at any of the concentrations used (n=4; p=NS; data 
not shown). 
 
PIK 75 inhibits vascular smooth muscle cell but not endothelial cell 
chemotaxis. 
In AoSMC and SVSMC treatment with PIK 75 (10 nM) significantly reduced 
PDGF-BB induced cell migration (n=5; p<0.01; figure 2A). In HAEC and HUVEC, PIK 
75 did not affect serum-inuduced chemotaxis (n=5; p=NS; figure 2B).  
 
Silencing of p110α inhibits proliferation of AoSMC but not HAEC. 
Incubation of AoSMC and HAEC with siRNA targeting p110α markedly 
decreased p110α protein expression in both cell types (n=4; p<0.01; figure 3A). This 
decrease in p110α was paralleled by a decreased proliferation of AoSMC (n=4; 
p<0.01 vs. control; figure 3B) but not HAEC (n=4; p=NS vs. control; figure 3B). 
 
PIK 75 exerts similar anti-proliferative and anti-migratory effects in AoSMC as 
rapamycin and paclitaxel, but not in HAEC. 
 
 
 
Treatment with PIK 75 (10 nM), rapamycin (10 nM), or paclitaxel (10 nM) 
resulted in a comparable inhibition of PDGF-BB (10 ng/ml) induced proliferation and 
migration (n=4; p<0.005; figure 4A) in AoSMC. In HAEC, however, only rapamycin 
and paclitaxel exerted anti-proliferative and anti-migratory effects while PIK 75 
remained inert toward endothelial cell growth and chemotaxis (n=4; p<0.005; figure 
4B). 
 
PIK 75 has no effect on endothelial senescence and eNOS expression. 
Incubation of HAEC with rapamycin (10 nM) and paclitaxel (10 nM) for 24 hours 
induced a senescent phenotype characterized by an enlarged and elongated cellular 
morphology. These morphological changes were not observed with PIK 75 (10 nM) 
(n=4; figure 5A). SA-β-gal assay confirmed enhanced senescence in HAEC treated 
with rapamycin or paclitaxel in contrast to PIK 75-treated cells (n=4; p<0.05; figure 
5B). Since eNOS is critically involved in both endothelial senescence and function, 
we assessed expression of total eNOS in HAEC by Western blot. Rapamycin and 
paclitaxel, but not PIK 75, decreased total eNOS expression in HAEC after 24h (n=4; 
p<0.005; figure 5C). 
 
PIK 75 inhibits endothelial TF and PAI-1 expression. 
Treatment of HAEC with either rapamycin (10 nM) or paclitaxel (10 nM) for 5 
hours induced basal TF expression (+47% and +48% respectively; n=4; p<0.05 vs. 
control; figure 6A) and enhanced TNF-α induced TF expression by 70% and 48% 
respectively (n=4; p<0.05 vs. TNF-α alone; figure 6B). In a similar manner, 
rapamycin and paclitaxel enhanced basal PAI-1 expression in HAEC (+79% and 
+140%; n=4; p<0.05 vs. Control; figure 6C). Treatment with PIK 75 abrogated basal 
and TNF-α induced TF (n=4; p<0.01 vs. control and; p<0.01 versus TNF-α alone; 
 
 
 
figure 6A and 6B) and PAI-1 expression (n=4; p<0.01 versus TNF-α alone; figure 6D) 
in HAEC.  
 
  
 
 
 
Discussion 
 
The small molecule inhibitor PIK 75 is an imidazopyridine developed in the 
context of a PI3-kinase drug discovery program (12). PIK 75 selectively inhibits the 
catalytic subunit p110α (IC50= 5.8 nM) encoded by the PIK3CA gene (16). Recent 
studies demonstrate a critical role for p110α in growth factor dependent signaling 
which may explain the selective mutation and overexpression of p110α associated 
with several types of cancer. However, the role of p110α activity in regulating 
vascular smooth muscle and endothelial cell proliferation and migration, two key 
mechanisms involved in restenosis and reendothelialization following DES 
implantation, remains unknown.  
PDGF-induced VSMC proliferation and migration are crucial cellular 
mechanisms triggering restenosis in coronary arteries following PTCA and in venous 
bypass grafts (17). This study demonstrates that pharmacological and genetic 
inhibition of p110α prevents arterial as well as venous VSMC proliferation in vitro. 
Consistent with this finding, p110α inhibition also impairs smooth muscle cell 
migration. The PI3K family consists of several isoforms with respect to the regulatory 
p85 and catalytic p110 subunits. The p85α and p110α isoforms are the most 
abundant in the vasculature. Studies on the p85α/p110α dimer showed that the p85α 
regulatory subunit inhibits the catalytic activity of p110α and that oncogenic p85α 
mutations act by disrupting the inhibitory contact with p110α (18,19). A more recent 
study demonstrated that phosphorylation of p85α at the serine 83 (pSer83) resulted 
in inhibition of VSMC and reduced neointima formation after balloon injury (20). In 
line with these findings, the present study demonstrates for the first time that direct 
pharmacological and genetic inhibition of p110α results in suppression of vascular 
 
 
 
SMC proliferation. Since p85α can interact with different p110 isoforms (α,β, and δ) 
and the expression of the p110 isoforms varies greatly between tissues, modulation 
of p85α activity and consecutive regulation of downstream cellular responses is likely 
complex and currently barely understood. In addition, to our knowledge there is 
currently no pharmacological activator of p85α available and reduction in neointima 
formation in response to Ser83-mutated p85α is inferior compared with the inhibition 
in response to rapamycin. In contrast, PIK 75 is a specific small molecule inhibitor of 
p110α and at the concentrations used in this study (0.1-10 nM) interactions with other 
isoforms can be excluded (16). Moreover, PIK 75 exerted similar antiproliferative and 
antimigratory effects on VSMC as compared to rapamycin and paclitaxel suggesting 
comparable effects on neonintima formation between these compounds, which is of 
relevance since maximal inhibition of luminal narrowing is a prerequisite in PTCA. 
Delayed arterial healing manifested by impaired reendothelialization and 
enhanced thrombogenicity remains a major concern associated with the use of DES, 
requiring continuous antiplatelet therapy in patients receiving these stents. 
Morphological studies have demonstrated a clear delay of reendothelialization in both 
rapamycin and paclitaxel eluting stents when compared with BMS (21). Indeed, 
rapamycin and paclitaxel have been shown to suppress EC proliferation and 
migration in several studies (14,22). In addition, by inducing a senescent phenotype 
and decrease in eNOS expression, recent data suggest that this drugs not only 
impair endothelial regrowth but also directly affect endothelial function (23). In line 
with this observation, rapamycin as well as paclitaxel exert direct prothrombotic 
effects on EC by enhancing both basal and cytokine induced expression of TF and 
PAI-1 (24,25). Importantly, most of these biological effects have also been observed 
with compounds used for second generation DES and suggest that the thrombotic 
risk of DES is a function of both, impaired endothelial coverage and function (26,27). 
 
 
 
In contrast to rapamycin or paclitaxel, inhibition of p110α, with PIK 75 or the 
corresponding siRNA, did neither affect proliferation nor migration in arterial or 
venous EC. These findings are supported by previous results showing that cell 
proliferation occurred normally in EC overexpressing activated p85α (20). Treatment 
with PIK 75 did neither induce endothelial senescence nor affect eNOS expression, 
which are both implicated in the endothelial dysfunction induced by rapamycin and 
paclitaxel. The suppression of basal and cytokine induced TF and PAI-1 expression 
associated with p110α inhibition is of particular relevance, since both proteins are 
critically involved in the pathogenesis of stent thrombosis (8). During acute coronary 
syndromes and PTCA, periprocedural cytokine plasma levels are increased to 
concentrations high enough to induced TF and PAI-1 expression in surrounding EC 
(28,29). The present study demonstrates that while rapamycin and paclitaxel 
enhance both basal and TNF-α induced TF and PAI-1 expression, p110α inhibition 
with PIK 75 exerts potent antithrombotic effects. 
 In summary, the present study provides evidence that inhibition of PI3K/p110α 
differentially regulates SMC and EC. In addition to its potent antiproliferative and 
antimigratory effects on SMC, targeting p110α also inhibits the expression of 
prothrombotic markers on EC. Since specific targeting of p110 isoforms is currently 
evaluated in different areas of modern medicine, we propose local p110α inhibition 
as a novel strategy in the context of DES design, in order to prevent restenosis 
without adding the risk of impaired reendeothelialization and enhanced 
thrombogenicity.  
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Figure Legend 
 
Figure 1. PIK 75 inhibits SMC proliferation while sparing endothelial growth. 
Treatment with PIK 75 inhibited proliferation of AoSMC and SVSMC in a 
concentration dependent manner (A; *p<0.05 versus control), while proliferation of 
HAEC and HUVEC was not affected (B, p=NS versus control). 
 
Figure 2. PIK 75 prevents SMC but not EC migration.  
Treatment with PIK 75 prevented PDGF-BB induced chemotaxis of AoSMC and 
SVSMC (A, *p<0.01 versus control). In contrast, PIK 75 treatment did not affect 
serum-induced migration of HAEC or HUVEC (B, p=NS versus control). 
 
Figure 3. Silencing of p110α inhibits proliferation of AoSMC but not HAEC. 
Treatment with the corresponding siRNA targeting resulted p110α resulted in a 
significant decrease in p110α protein expression in both cell types (A, *p<0.01 versus 
control). Silencing of p110α inhibited proliferation of AoSMC only, while proliferation 
of HAEC remained unaltered (B, p=NS versus control). 
 
Figure 4. Similar anti-proliferative and anti-migratory effects of PIK 75 in 
AoSMC than rapamycin and paclitaxel. 
PIK 75 exerts similar effects on AoSMC migration and proliferation when compared 
with rapamycin and paclitaxel (A, *p<0.005 versus control). In contrast to rapamycin 
and paclitaxel, treatment with PIK 75 does not affect proliferative and migratory 
capacity of HAEC (B, *p<0.005 versus control). 
 
 
 
 
Figure 5. PIK 75 has no effect on endothelial senescence or eNOS expression. 
In contrast to rapamycin or paclitaxel, treatment with PIK 75 does not induce 
senescence in HAEC as determined by morphological analysis (A, magnification 20x) 
or β-galactosidase staining (B, *p<0.05 versus control and PIK 75 treated cells). 
Treatment with PIK 75 does not modulate eNOS expression (C). 
 
Figure 6. p110α inhibition suppresses endothelial TF and PAI-1 expression. 
Treatment with PIK 75 inhibited basal (A) and TNF-α induced (B) TF expression in 
HAEC (*p<0.01 vs control and *p<0.01 versus TNF-α alone), whereas rapamycin and 
paclitaxel enhanced TF expression under both conditions (**p<0.05 versus control 
and TNF-α alone). Rapamycin and paclitaxel also enhanced PAI-1 expression under 
basal conditions (C, *p<0.05 versus control). Treatment with PIK 75 inhibited TNF-α 
induced PAI-1 expression in HAEC (D, *p<0.01 versus TNF-α alone).  
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